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ABSTRACT 
Hereditary transthyretin amyloidosis (ATTR amyloidosis) is a multi-system 
protein folding disorder that results from >100 described mutations in the 
transthyretin (TTR) gene. In the disease, non-natively folded TTR, originally 
produced by the liver, travels throughout circulation and deposits extracellularly at 
downstream target organs. The multi-tissue etiology of the disease makes it 
difficult to study in vitro, while no mouse model accurately recapitulates disease 
pathology. Therefore, we utilized patient-specific induced pluripotent stem cells 
(iPSCs) to test the hypothesis that production of and exposure to destabilized 
TTRs results in distinct cellular and molecular changes.    
The liver’s contribution to the deposition of TTR at distal tissues is 
understudied. As a result, in Aim 1 we sought to assess the effects of destabilized 
TTR production on effector hepatic cells. To this end, we utilized gene editing to 
generate isogenic, patient iPSCs expressing either mutant or wild-type TTR. 
Combining this tool with single cell RNAseq, we identified hepatic proteostasis 
factors,  including unfolded protein response (UPR) pathways, whose expression 
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coincided with the production of destabilized TTR. Enhancing endoplasmic 
reticulum (ER) proteostasis within patient hepatic cells via exogenous activation of 
adaptive UPR signaling, we demonstrated preferential reduction in the secretion 
of pathogenic TTR. In turn, we demonstrated that production of disease-associated 
TTR correlates with expression of proteostasis factors capable of regulating TTR 
secretion and in turn downstream pathogenesis. 
ATTR amyloidosis patients exhibit extreme phenotypic variation (e.g.  TTR 
fibril deposits at cardiac tissue and/or peripheral nerves). In Aim 2, we sought to 
define responses of target cell types to pathologically-diverse TTRs. To 
accomplish this, we profiled transcriptomic changes resulting from exposure to a 
variety of destabilized TTRs to determine 1) target cell response to TTR exposure 
and 2) how this response changes across diverse variants and cell types. In doing 
so, we found that TTR exposure elicits distinct variant- and cell type-specific 
transcriptional responses.  
 Herein, we addressed our central hypothesis by profiling destabilized TTR 
production within hepatic cells and TTR  exposure at target cell types. Collectively, 
these data may result in the discovery of unidentified and potentially druggable 
pathologically-associated pathways for ATTR amyloidosis and other systemic 
amyloid diseases. 
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CHAPTER ONE. UTILIZATION OF PATIENT-SPECIFIC INDUCED 
PLURIPOTENT STEM CELLS FOR PRE-CLINICAL MODELS OF SYSTEMIC 
AMYLOID DISEASE. 
1.1 Introduction 
Systemic amyloid disease refers to a diverse class of complex, devastating 
disorders affecting over 1 million individuals worldwide (Blancas-Mejia et al. 2013; 
Buxbaum 2004; Falk et al. 1997; Merlini and Westermark 2014; Wechalekar et al. 
2016). In these diseases, effector organs/cell types secrete proteins which 
ultimately misfold, travel throughout circulation, and physically deposit on 
downstream target cell types, eliciting toxicity and eventual organ dysfunction 
(Blancas-Mejia et al. 2013; Buxbaum 2004; Falk et al. 1997; Merlini and 
Westermark 2014; Wechalekar et al. 2016). The most common systemic amyloid 
disease for example, light chain (AL) amyloidosis involves the multi-system 
deposition of proteotoxic, misfolded antibody light-chain (LC) fragments secreted 
by malignant plasma cells (Blancas-Mejia et al. 2013; Buxbaum 2004; Falk et al. 
1997; Merlini and Westermark 2014; Wechalekar et al. 2016).  
Transthyretin amyloidosis (ATTR amyloidosis), is thought to be the second 
most common systemic amyloid disease. In the disease, misfolded transthyretin 
(TTR), originally produced by the liver, travels throughout circulation and physically 
deposits on target cell types (e.g. peripheral nerves and/or cardiac tissue). ATTR 
amyloidosis can result from inherited mutations (hereditary ATTR amyloidosis) or 
sporadically in an aging-associated manner (wild-type ATTR amyloidosis) (Ando 
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et al. 2005; Benson 2012; Gertz et al. 2015; Reixach et al. 2004; Ruberg and Berk 
2012). Although historically considered rare, recent advances in clinical treatment 
and diagnostics for the disease will likely lead to an accelerated rise in prevalence. 
In line with this, recent post-mortem studies found cardiac TTR amyloid fibrils 
(associated with wild-type ATTR amyloidosis onset) in 25% of individuals over 80 
years of age (Ruberg and Berk 2012).  
ATTR amyloidosis is extraordinarily complex, with diverse pathologies and 
disease progression due in part to the sex and genetic background of the patient 
(Ando et al. 2005; Benson 2012; Gertz et al. 2015; Reixach et al. 2004; Ruberg 
and Berk 2012). Moreover, many systemic amyloid diseases are strongly linked to 
aging, perhaps due to the well-documented collapse in protein homeostasis 
(proteostasis) machinery which regulates the folding and quality of secreted 
proteins (Ando et al. 2005; Benson 2012; Gertz et al. 2015; Hipps et al. 2019; 
Kaushik and Cuervo 2015; Labbadia and Morimoto 2015; Reixach et al. 2004; 
Ruberg and Berk 2012). Due to the complex, multi-tissue etiology of these 
diseases, coupled with their strong association with age and dependence on 
genetic background of the individual, pre-clinical models (both in vivo and in vitro) 
of the systemic amyloid diseases are limited. In turn, cellular and molecular 
understandings of these disorders remain elusive. In order to better understand 
and develop novel therapeutics for diseases such as ATTR amyloidosis, our 
laboratory has employed induced pluripotent stem cell (iPSC)-based models in a 
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precision medicine approach (Giadone et al. 2018; Leung et al. 2013; Leung and 
Murphy 2016). 
Herein, we will describe the history of iPSCs as well as their potential for 
modeling and understanding systemic amyloid disorders. We will also discuss the 
potential for iPSCs to improve the efficiency of drug discovery. In doing so, we will 
survey recent achievements in iPSC platforms for modeling protein folding 
disorders as well as discuss future applications and the potential for new pre-
clinical models of additional amyloid disorders with tremendous unmet medical 
need. 
 
1.2 DRUG DISCOVERY: FROM PRE-CLINICAL EXPERIMENTS TO CLINICAL 
TRIALS 
The process of drug discovery for developing novel therapeutic compounds 
involves pre-clinical in vitro efficacy studies, followed by additional in vivo efficacy 
and toxicity studies utilizing animal models, and lastly three phases of clinical trials. 
The cost to bring one compound to market is currently $2.6 billion (Avorn 2015; 
Brodniewicz and Grynkiewicz 2010; Wong et al. 2019).  
The drug discovery pipeline often begins through screening of small 
molecule libraries containing thousands of compounds for efficacy in in vitro 
immortalized cell models or ability to bind a protein of interest (Avorn 2015; 
Brodniewicz and Grynkiewicz 2010; Wong et al. 2019). Alternatively, candidate 
compounds can be identified as natural products (including metabolites from 
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plants) or through repurposing of already Food and Drug Administration (FDA) 
approved drugs (often included within small molecule libraries) (Ashburn and Thor 
2004; Balunas and Kinghorn 2005; Li and Vederas 2009). Following identification 
of potential compounds for follow-up study, novel compounds are assessed for in 
vivo toxicity and efficacy in ameliorating disease-associated phenotypes in animal 
models (i.e. tolerability of the compound in certain routes of administration and 
doses) (Giadone et al. 2018; Brodniewicz and Grynkiewicz 2010). If deemed 
successful, an investigational new drug (IND) application is established; pending 
approval by the FDA, the new compound will move into phase I-III clinical trials, on 
average lasting approximately five years. The probability that an IND compound 
will successfully complete all clinical trials and make it to market post-approval is 
estimated to be approximately 13.8% (Avorn 2015; DiMasi et al. 2010; Wong et al. 
2019). 
The clinical trial paradigm is extraordinarily costly and time-consuming, with 
an average time from pre-clinical animal model to market of approximately 12 
years (Roses 2008). Developing more robust pre-clinical models, which includes 
more cell models better equipped to determine efficacy and toxicity in multiple 
genetic backgrounds and cell types, represents a potential avenue for reducing the 
failure rate, time, and cost of drug approval. 
 
1.3 NON-HUMAN ANIMAL MODELS OF HUMAN DISEASE 
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Prior to entering clinical trials, novel compounds are first evaluated for efficacy and 
toxicity in pre-clinical models composed of both in vitro cell culture-based 
experiments and in vivo animal models. Traditional in vitro studies of cell biology 
rely on the use of immortalized cell lines often derived from human primary tissue 
(Brodniewicz and Grynkiewicz 2010; Giadone et al. 2018). Though insightful, cell 
lines represent the genetic background of a singular person. As a result, it is often 
difficult to extrapolate findings made in one individual cell line to other lines, 
animals, and eventually humans. This limitation is likely one contributor to the large 
failure rates seen in drug discovery. At the same time, immortalized cell lines are 
generated via infection of oncogenic viruses such as simian virus 40 (SV40)-
associated large T antigen or overexpression of human telomerase (An et al. 2012; 
Ramboer et al. 2014). Although immortalization techniques are relatively straight 
forward and highly efficient, these methods often lead to large, karyotypic 
abnormalities – an additional source of factors potentially confounding 
investigations into the cells or tissues from which these lines were derived (Toouli 
et al. 2002). 
In vivo animal (including mouse, non-human primate, and zebrafish) models 
of disease, have long been valued as a gold standard for understanding disease 
and determining the efficacy of novel pharmaceutical agents in pre-clinical studies 
(Ericsson et al. 2013; Rosenthal and Brown 2007). The current paradigm for the 
utilization of animal models involves two modalities: utilizing animals as surrogates 
for disease to understand/characterize mechanisms of pathogenesis or utilizing 
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animals to assess pharmacologic-associated toxicity and toxicology (Brodniewicz 
and Grynkiewicz 2010; Wong et al. 2019). Developing mouse models of human 
disease, researchers can employ several strategies. In one approach, disease-
associated DNA variants (including pathogenic mutations and/or regulatory 
sequences) can be introduced into the organism’s genome in an attempt to 
recapitulate disease ontogeny and phenotype (Ericsson et al. 2013; Rosenthal and 
Brown 2013; Yu and Bradley 2001). Generation of genetically altered mice in this 
way relies on the isolation and manipulation of mouse embryonic stem cells 
(mESCs). To this end, a transgene can be exogenously expressed by introducing 
additional copies into the mESC genome. Alternatively, expression of genes can 
be attenuated by targeting and disrupting exonic regions of a gene of interest (GOI) 
in a constitutive or conditional, cell-type specific manner. Through the use of Cre 
recombinase, genomic regions flanked by LoxP sites can be excised. Generating 
a mouse in which Cre recombinase expression is driven by a cell- or tissue-specific 
promoter will result in Cre production in that particular site. When crossed with a 
mouse engineered with LoxP sites flanking a GOI, this can result in offspring 
whose GOI is no longer expressed in the cell or tissue type of interest (Ericsson et 
al. 2013; Rosenthal and Brown 2013; Yu and Bradley 2001). This can be of 
particular use when disrupting regulatory sequences to exacerbate a disease 
phenotype (Buxbaum 2009).  
In the development of most animal models of human disease, it is assumed 
that the model recapitulates some aspect of human disease-associated phenotype 
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and that this phenotype is driven by etiological mechanisms that are similar in both 
humans and the model organism in question (McGonigle and Ruggeri 2014). 
Problematically however, this limits the robustness of animal models for diseases 
whose causal mechanisms are unclear. In some cases, such as hereditary ATTR 
amyloidosis, mouse models fail to recapitulate many key aspects of human 
disease pathology and therefore limit their effectiveness in determining the efficacy 
of new therapeutics (Buxbaum 2009). Similarly, animal models of complex 
diseases whose causes are either unknown or involve combinatorial interactions 
of multiple driver mutations and/or non-coding variants (e.g. Alzheimer’s Disease, 
Parkinson’s, multiple sclerosis, etc.) have had limited success in predicting efficacy 
of novel therapeutic compounds (McGonigle and Ruggeri 2014). Utilizing iPSCs, 
containing the entire genetic context of the individual from which the line was 
derived, to model human disease takes an agnostic or ‘blackbox’ approach to 
determining disease etiologies. Unlike non-human animal models, patient-specific 
iPSCs allow researchers to perform in vitro experiments to recapitulate disease 
phenotype without necessitating a mechanistic understanding how said disease 
arises (Giadone et al. 2018; Leung et al. 2013; Leung and Murphy 2016; Park et 
al. 2017). Additionally, development of animal models which require the knocking-
in of disease-associated mutations, result from overexpression of the mutant in a 
single genetic background. As a result, this severely limits understanding how 
diverse genetic backgrounds affects disease pathogenesis and therapeutic 
potential. IPSCs, described below, maintain the entire genetic context of the 
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individual from which the line was derived and thus hold the potential to elucidate 
the effects of ethnicity and genetic background on disease mechanism as well as 
drug efficacy and safety. 
 
1.4 INDUCED PLURIPOTENT STEM CELLS 
During the mid- to late-2000s, the field of iPSC biology was founded and expanded 
rapidly (Shi et al. 2017). In 2006, Takahashi and Yamanaka published their 
seminal work describing the creation of pluripotent stem cells derived from murine 
tail tip fibroblasts which could be cultured and differentiated into cell types of any 
of the three germ layers in vitro (Takahashi and Yamanaka 2006). One year later, 
the same group reported the generation of iPSCs from human fibroblasts by 
overexpressing key developmental transcription factors (OCT4, KLF4, SOX2, and 
C-MYC) termed Yamanaka factors via lentiviral transduction (Takahashi et al. 
2007). The following years saw exponential growth for iPSC biology as a field, 
involving studies of reprogramming, pluripotency, and differentiation toward a 
number of diverse cell lineages (Shi et al. 2017). With these works, reprogramming 
efficiencies increased and methodologies were standardized. Presently, iPSC 
lines are typically generated from human fibroblasts or peripheral blood 
mononuclear cells (PBMCs) via transient overexpression of Yamanaka factors 
achieved using non-integrating Sendai virus infection (Shi et al. 2017). In 2012, 
Shinya Yamanaka was awarded the Nobel Prize in Medicine or Physiology – the 
shortest time of discovery to award in history (Shi et al. 2017). 
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IPSCs, capable of indefinite self-renewal and differentiation into any cell 
type of the body, provide novel avenues for both studying human development and 
disease as well developing broadly efficacious therapeutics. Patient-specific 
iPSCs provide the ability to study disease in the context of the entire genetic 
background of the individual from which the line was derived, a characteristic 
important for the study of many genetic disorders (Park et al. 2017; Shi et al. 2017). 
Many libraries of iPSCs derived from genetically diverse patients with complex, 
race and sex-associated disorders such as Sickle Cell Disease, ATTR 
amyloidosis, and alpha-1 anti-trypsin deficiency have now been generated with the 
potential for evaluating disease progression in diverse cell types (Giadone et al. 
2018; Park et al. 2017). Moreover, iPSC lines included within these libraries are 
frequently associated with large amounts of deep clinical data associated with the 
patient from which the line was reprogrammed. In line with this, several groups 
have begun constructing a catalog of iPSC lines from individuals within the highly 
characterized Framingham Heart Study cohort. 
As mentioned previously, current cell lines utilized in pre-clinical models of 
disease frequently contain confounding karyotypic abnormalities (Toouli et al. 
2002). The reprogramming of adult-type cells to iPSCs however, is infrequently 
associated with such chromosomal aberrations. To obviate concerns associated 
with this, researchers regularly assess the karyotype of iPSC lines across 
passages, experiments, and genetic manipulation (e.g. gene editing) via 
methodologies such as G-banding (Giadone et al. 2018, Park et al. 2017, Shi et 
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al. 2017). The declining cost and increasing availability of genome sequencing 
have increased the prevalence of genome wide association studies (GWAS), 
identifying single nucleotide polymorphisms (SNPs) correlating with disease states 
(Visscher et al. 2017). Interestingly, much work now highlights the potential 
contribution of non-coding regulatory elements (e.g. enhancers and repressors) 
within the genome for eliciting changes in chromatin architecture and accessibility 
of transcription factor binding sites and eliciting disease (Zhang and Lupski 2015). 
Patient-specific iPSCs maintain the entire coding and non-coding genome of the 
individual from which the line was derived. The use of high-quality iPSC lines, free 
of karyotypic abnormalities, allows for agnostic studies into the contribution of non-
coding elements of the genome (including chromatin architecture) to the 
development of diverse diseases.   
There are several limitations to be noted, however, associated with the use 
of iPSCs for modeling disease. For example, the reprogramming process erases 
a vast majority of epigenetic changes associated with aging in the adult cells from 
which the iPSC line was generated (Krishnakumar and Blelloch 2013). As a result 
of this, utilization of iPSCs to model aging-associated disorders and biological 
decline remains limited. Despite this however, efforts have been made to artificially 
mimic the effects of aging in vitro, including overexpression of genes associated 
with pre-mature aging disorders such as Progeria as well as utilizing patient-
derived fibroblasts (maintaining epigenetic modifications) capable of 
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transdifferentiating into alternative, potentially disease-associated cell types (e.g. 
neuronal cells) (Mertens et al. 2018).  
 
1.5 PATIENT-DERIVED IPSCS FOR DISEASE MODELING AND PRECISION 
MEDICINE 
With examples ranging from neurodegenerative disorders (e.g. spinal muscular 
atrophy, SMA) to liver-derived protein folding disorders (e.g. α1-antitrypsin 
deficiency, AATD), iPSC-based models of diverse disorders have contributed a 
considerable amount to our understanding of human disease (Adami and Bottai 
2019; Kaserman and Wilson 2018; Ng et al. 2015; Rodriguez-Muela et al. 2008; 
Tafaleng et al. 2015; Wilson et al. 2015). 
SMA, the most common genetic-based disease responsible infant death, is 
a devastating degenerative motor neuron disorder. Most often resulting from 
homozygous deletion of the survival of motor neuron 1 (SMN1) gene, patients with 
SMA exhibit motor neuron cell death within the spinal cord and eventual loss of 
motor function (Adami and Bottai 2019; Ng et al. 2015; Rodriguez-Muela et al. 
2008). Although advances in our understanding of the disease have come from 
animal models of SMA, key differences in the regulation and processing of SMN1 
exist between human and other species, thus limiting their utility (Adami and Bottai 
2019). This fact, coupled with the inaccessibility of the disease-associated cell type 
(i.e. motor neurons of the spinal cord), highlight the ideal candidacy of iPSCs for 
modeling SMA. 
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To these ends, a number of studies have demonstrated the ability to 
generate iPSC lines from multiple individuals with various forms of SMA from a 
variety of source material (including fibroblasts as well as pre-natal chorionic villus 
samples) (Adami and Bottai 2019; Ng et al. 2015; Rodriguez-Muela et al. 2008). 
By differentiating patient-specific iPSC lines into motor neurons (MNs), groups 
have demonstrated differential levels of apoptosis in iPSC-derived MNs that 
correlate with levels of SMN expression – a finding which recapitulates clinical 
observations (Adami and Bottai 2019). Interestingly, by differentiating SMN iPSCs 
into MNs and generating transcriptomic profiles via RNA sequencing, Ng et al. 
identified a gene expression signature constituting activation of endoplasmic 
reticulum (ER) stress and unfolded protein response (UPR)-associated signaling 
components – a surprising observation given that SMA was not previously known 
to involve protein misfolding or mistrafficking (Rodriguez-Muela et al. 2008). 
Despite this however, follow-up studies have since identified novel roles for SMN 
in regulating splicing of mRNAs encoding chaperone proteins which in turn 
regulate the proper folding of newly made proteins (Rodriguez-Muela et al. 2008). 
It is therefore possible that decreased levels of SMN results in decreased levels of 
functional chaperones, increases in misfolded proteins, and eventually ER stress. 
Furthermore, Rodriguez-Muela et al. demonstrated novel roles for autophagy-
mediated clearance of SMN, observing overactive mTORC1 signaling and 
resulting hyperactive autophagic clearance of SMN in patient iPSC-derived MNs. 
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In the case of SMA, iPSCs have revealed unexpected roles for ER stress and 
proteostasis pathways in modulating pathogenesis of the disease. 
AATD is the most prevalent inherited liver disease in the United States 
(Kaserman and Wilson 2018; Tafaleng et al. 2015; Wilson et al. 2015). In patients 
with AATD, destabilizing mutations within the α-1 anti-trypsin (A1AT) gene, result 
in misfolding and polymerization of the respective protein product (Kaserman and 
Wilson 2018; Tafaleng et al. 2015; Wilson et al. 2015). In healthy individuals, A1AT 
is secreted from the liver and subsequently travels to the lung where it acts as an 
inhibitor of chymotrypsin secreted by circulating neutrophils. Although a 
monogenic disorder, patients with A1AT mutations can present with wide-ranging 
severity and symptomatology (Kaserman and Wilson 2018; Tafaleng et al. 2015; 
Wilson et al. 2015). Some individuals for example present with profound liver 
disease, while others exhibit lung phenotypes such as chronic obstructive 
pulmonary disease (COPD), due to a lack of functional A1AT trafficking to the lung. 
Polymerized A1AT subsequently accumulates within the liver of patients with the 
disease and can eventually result in liver toxicity. Generation of AATD patient-
specific iPSC-derived hepatocyte-like cells (HLCs) have identified upregulation of 
numerous ER stress and proteostasis machinery components correlating with 
aggregated A1AT polymers (Kaserman and Wilson 2018; Wilson et al. 2015). 
Interestingly, HLCs differentiated from AATD patients with varying severity (with 
and without clinically-significant liver disease) demonstrated a number of ER-
associated phenotypic differences (Tafaleng et al. 2015). For example, HLCs of 
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patients with severe liver disease exhibited globular inclusions within the rough ER 
compared to HLCs from AATD patients without liver disease by electron 
microscopy (Tafaleng et al. 2015). In this instance, iPSC-based modeling of AATD 
recapitulates relatively nuanced differences in clinical presentation of patients with 
the disease.  
 As proof-of-principle for precision medicine approaches of iPSC-based 
disease modeling, Terrenoire et al. utilized long QT syndrome (LQTS) patient 
iPSC-derived cardiomyocyte-like cells (iPSC-CMs) to evaluate the efficacy of 
several putative treatment regimens for the patient from which the line was derived. 
LQTS is a life-threatening condition resulting from mutations within ion channels 
resulting in sporadic arrhythmias of cardiac tissue within structurally normal hearts 
(Schwartz et al. 2012; Terrenoire et al. 2013). Problematically, the disease can 
result from diverse genetics including multiple driver mutations and genetic 
modifiers, often occurring simultaneously. With this, LQTS proves difficult to 
manage clinically, as patients exhibit varying degrees of responsiveness to 
treatments depending upon their disease-driving mutation (Schwartz et al. 2012; 
Terrenoire et al. 2013).   
 In an early application of disease modeling, researchers generated iPSCs 
from fibroblasts of a pediatric patient with two LQTS-associated mutations (one 
inherited from both parents and one sporadic). Problematically, each mutation is 
associated with discrete clinical treatments. In order to determine which is 
responsible for the clinical manifestation of the disease and thus determine which 
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treatment regimen will be most effective, Terrenoire et al. generated iPSCs from 
the patient as well as his or her parents, and subsequently generated iPSC-CMs. 
By comparing the patient’s iPSC-CMs to those of the parents’, it was found that 
although each line contained the inherited mutation, only the patient iPSC-CMs 
exhibited sporadic arrhythmia via electrophysiology. This suggested that the 
clinical disease observed in the patient resulted from the de novo mutation. As a 
follow-up study, in order to determine the most effective treatment option, the 
patient’s iPSC-CMs were exposed to a variety of treatment regimens (including 
multiple doses and multi-drug combinations), and their response was determined 
via electrophysiology. In doing so, they found that low concentrations of mexiletine 
was effective in reducing arrhythmias in vitro and eventually in the patient 
(Terrenoire et al. 2013). 
It is worth noting that the use of iPSCs as cell-based therapeutics for 
monogenic disorders is largely contingent upon advances in tissue engineering as 
well as differentiation protocols. Despite these limitations however, the above 
noted cases provide direct examples where iPSC-based disease models have 
already lent great insight into the basic biology of disease as well as aspects of 
clinical treatment.         
  
1.6 NOVEL THERAPEUTIC DEVELOPMENT IN THE SYSTEMIC AMYLOID 
DISEASES 
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Over 1 million individuals worldwide suffer from a systemic amyloid disease 
(Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 1997; 
Merlini and Westermark 2004; Wechalekar et al. 2016). These disorders typically 
result from a destabilizing mutation which in turn increases the propensity for 
misfolding of the associated protein. Systemic amyloid diseases have complex 
disease pathogenesis involving multiple tissue types: destabilized or misfolded 
proteins are first produced by an effector organ, secreted into circulation, and 
eventually deposited at distal target cell types (Figure 1.1). Eventually, these 
disorders are characterized by the deposition of large, insoluble β-sheet rich 
amyloid fibrils comprised largely of the mutant protein. In the most common 
systemic amyloid disease, light chain (AL) amyloidosis, cancerous monoclonal 
plasma cells secrete light chain antibody fragments (Merlini et al. 2018). Over time, 
these light chain fragments accumulate and form proteotoxic fragments and 
eventual amyloid fibrils at distal target organs including the liver, heart, and 
kidneys.   
 Systemic amyloid diseases result from the misfolding and aggregation of 
over 30 structurally distinct proteins, whose deposition ultimately leads diverse 
organ dysfunction and disease (Blancas-Mejia and Ramirez-Alvarado 2013; 
Buxbaum 2004; Falk et al. 1997; Merlini and Westermark 2004; Wechalekar et al. 
2016) (outlined in Figure 1.1). Due in large part to the diversity of proteins eliciting 
these disorders, development of broadly acting therapeutics has proven difficult.  
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Figure 1.1 Systemic amyloid disease pathogenesis.  
(Top) Representation of the overall steps comprising systemic amyloid disease 
pathogenesis, from protein production and initial folding, to secretion and 
misfolding, followed by deposition at diverse tissue types. (Bottom) Descriptions of 
light chain-associated AL and ATTR amyloidosis including effector organs, overall 
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The current therapeutic paradigm for these diseases partly involves developing 
kinetic stabilizing compounds or antibodies to either stabilize the native protein or 
disrupt amyloid fibrils (Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; 
Falk et al. 1997; Merlini and Westermark 2004; Wechalekar et al. 2016, Hosoi et 
al. 2016). Resulting from the pathologic misfolding of diverse proteins however, 
development of these compounds proves to be an onerous task – requiring 
assessment and validation for each protein (i.e. a unique stabilizer for each 
structure). In spite of the diversity of disease-associated proteins, the common 
mechanism shared by all is the production and secretion of destabilized proteins 
via effector organs. As a result, researchers are working to understand the 
contribution of proteostasis machinery within effector cells in order to identify 
potentially druggable therapeutic pathways – information leverageable for the 
development of broadly efficacious therapeutics the systemic amyloid diseases 
(Chen et al. 2014; Plate et al. 2016; Shoulders et al. 2013).   
 After being transcribed and translated, many nascent polypeptides are 
shuttled into the ER to undergo a number of complex, chaperone-mediated folding 
events and post translational modifications, to ultimately form a functional protein 
product. Proper folding of newly translated polypeptides and degradation of 
misfolded protein products is regulated by signaling pathways termed proteostasis 
networks (Chen et al. 2014; Hipps et al. 2019; Plate et al. 2016; Shoulders et al. 
2013). These networks, including the UPR, play important roles in maintaining the 
fidelity of the proteome in instances of stress, disease, and homeostasis (Hipps et 
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al. 2019; Walter and Ron 2011). The UPR is regulated by three transmembrane 
receptors within the lumen of the ER: IRE1, ATF6, and PERK (Chen et al. 2014; 
Glembotski et al. 2019; Hetz 2012; Hipps et al. 2019; Plate et al. 2016; Shoulders 
et al. 2013; Walter and Ron 2011) (Figure 1.2). When unfolded or misfolded 
proteins accumulate within the cell (perhaps due to destabilizing mutations), 
molecular chaperones such as HSPA5 interact with these proteins and in turn can 
activate the three arms of the UPR. Activation of these pathways lead to 
translocation of cognate transcription factors to the nucleus, upregulation of distinct 
yet shared transcriptional signatures, and various functional consequences (Chen 
et al. 2014; Glembotski et al. 2019; Hetz 2012; Hipps et al. 2019; Plate et al. 2016; 
Shoulders et al. 2013; Walter and Ron 2011). Activation of the adaptive arms of 
the UPR, mediated by IRE1 and ATF6 signaling, leads to upregulation of 
components of the ubiquitin proteasome system and ER associated degradation 
(ERAD) pathway components (Chen et al. 2014; Glembotski et al. 2019; Hetz 
2012; Hipps et al. 2019; Plate et al. 2016; Shoulders et al. 2013; Walter and Ron 
2011). Activation of these pathways works to selectively target and degrade 
misfolded, potentially toxic protein species, limiting their secretion (Chen et al. 
2014; Glembotski et al. 2019; Hetz 2012; Hipps et al. 2019; Plate et al. 2016; 
Shoulders et al. 2013; Walter and Ron 2011). At the same time, adaptive UPR 
activation leads to upregulation of genes associated with chaperone function as 
well as an increase in the size of the ER to facilitate an increase in folding capacity 
(Hipps et al. 2019; Walter and Ron 2011). Chronic UPR activation on the other  
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Figure 1.2 Activation of UPR-associated signaling pathways upon detection 
of misfolded proteins.  
The detection of misfolded proteins within the lumen of the ER by molecular 
chaperones such as HSPA5 (BiP), results in activation of IRE1, ATF6, or PERK 
signaling. Activation of each arm results in transcriptional activation of specific 
target genes as well as activation of functional pathways in order to cope with the 
production of misfolded protein. Target genes listed were selected from Grandjean 
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hand, triggered in part by excessively large quantities of misfolded proteins, 
activates the PERK signaling pathway, whose functional downstream 
consequence includes synthesis and activation of pro-apoptotic machinery (Chen 
et al. 2014; Glembotski et al. 2019; Hetz 2012; Hipps et al. 2019; Plate et al. 2016; 
Shoulders et al. 2013; Walter and Ron 2011).  
Endogenous signaling pathways such as the UPR may represent 
druggable, broadly efficacious therapeutic strategies for patients with systemic 
amyloid diseases (Chen et al. 2014; Glembotski et al. 2019; Hetz 2012; Plate et 
al. 2016; Shoulders et al. 2013). In line with this rationale, recent progress has 
been made to target and activate endogenous signaling pathways associated with 
protein folding surveillance and quality control machinery (Chen et al. 2014; Plate 
et al. 2016; Shoulders et al. 2013). Below we will discuss the potential for 
exogenous stress-independent activation of the adaptive UPR in modulating 
aspects of ATTR amyloidosis pathogenesis.    
 
1.7 HEREDITARY ATTR AMYLOIDOSIS 
ATTR amyloidosis involves the misfolding and subsequent aggregation of TTR at 
downstream target organs such as the heart and peripheral nerves, ultimately 
resulting in cell death and organ dysfunction. ATTR amyloidosis can be sporadic 
or inherited (termed wild-type and hereditary ATTR amyloidosis, respectively) 
(Ando et al. 2005; Benson 2012; Gertz et al. 2015; Giadone et al. 2018; Reixach 
et al. 2004; Ruberg and Berk 2012). TTR is produced primarily by the liver, with 
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some synthesis in the pancreas and choroid plexus (Jacobsson 1989). Its currently 
accepted primary function is to serve as a transporter of retinol and thyroxine 
binding protein throughout the body. Hereditary ATTR amyloidosis is understood 
to be a rare disease, affecting roughly 50,000 people worldwide. Wild-type ATTR 
amyloidosis, however, is thought to be much more common, with one post-mortem 
autopsy study estimating ATTR fibrils present in approximately 25% of individuals 
over 80 years of age (Cornwell 3rd et al. 1983; Tanskanen et al. 2008; Westermark 
et al. 2003). It is currently thought that ATTR amyloidosis will likely overtake AL 
amyloidosis as the most prevalent systemic amyloid disease worldwide. Hereditary 
ATTR amyloidosis symptoms typically manifest in the 5th or 6th decade of life 
(though this can vary depending on the mutation), while wild-type disease 
manifests in the 8th decade (Ando et al. 2005; Benson 2012; Gertz et al. 2015; 
Giadone et al. 2018; Reixach et al. 2004; Ruberg and Berk 2012). 
Currently, amyloidosis is diagnosed by histologically staining a fat aspirate 
biopsy or the affected organ with Congo red – a dye which preferentially stains 
amyloid fibrils. Mass spectrometry (MS) is then performed to identify Congophilic 
protein species (Ando et al. 2005; Benson 2012; Gertz et al. 2015; Giadone et al. 
2018; Reixach et al. 2004; Ruberg and Berk 2012). Complicating our 
understanding and treatment of the disease, a lack of approved biomarkers 
coupled with a subtle and systemic onset of symptomatology make the disease 
notoriously difficult to diagnose (Ando et al. 2005; Benson 2012; Gertz et al. 2015; 
Giadone et al. 2018; Reixach et al. 2004; Ruberg and Berk 2012).  
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Historically, standards of care for patients with ATTR amyloidosis have 
included liver transplantation to remove the source of circulating amyloidogenic 
TTR (Figure 1.3). Despite this however, not all patients are candidates for surgery 
due to age or disease progression, while at the same time donor organ deficits 
exist. Alternatively, small molecule kinetic stabilizers such as diflunisal (a 
repurposed nonsteroidal anti-inflammatory drug, NSAID) and tafamidis (a 
synthetic compound, Vyndaqel) work by binding and stabilizing tetrameric TTR, 
limiting monomerization and subsequent misfolding from occurring (Ando et al. 
2016; Berk et al. 2013; Buxbaum 2019; Maurer et al. 2017; Maurer et al. 2018). 
Tafamidis recently received FDA approval for treatment of peripheral neuropathy, 
while diflunisal is approved for both cardiomyopathy and peripheral neuropathy.  
Despite success in clinical trials for both compounds, patients exhibit large 
variations in responsiveness, likely due to their inherited TTR mutation (Ando et al. 
2016; Berk et al. 2013; Buxbaum 2019; Maurer et al. 2017; Maurer et al. 2018). In 
addition, first-in-class RNA interference (RNAi)-based therapeutics, Inotersen and 
Patisiran, have been developed for hereditary ATTR amyloidosis. Inotersen 
(TEGSEDI) and Patisiran (ONPATTRO) work via slightly different mechanisms 
(antisense oligonucleotide versus siRNA, respectively), but are both delivered via 
GalNac-coated lipid nanoparticles which selectively target the liver (Adams et al. 
2018; Benson et al. 2018; Butler et al. 2016; Buxbaum et al. 2017; Buxbaum 2018). 
Both have recently received FDA approval for use in ATTR amyloidosis patients 
with polyneuropathy (Gales 2019). Despite the recent advent of therapeutics for  
 




Figure 1.3 ATTR amyloidosis pathogenesis and novel therapeutic strategies. 
Mechanisms of ATTR amyloidosis pathogenesis including novel therapeutic 
strategies (such as RNAi methodologies, liver transplantation, and kinetic 
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the disease, the most effective treatment regimen (including multi-drug 
combination and dosage) is likely dependent on the individual. 
 The genetics of ATTR amyloidosis is highly complex, with wide-ranging 
prevalence and penetrance largely depending on the inherited mutation and/or 
ethnicity of the patient. As stated previously, the current global prevalence of 
hereditary ATTR amyloidosis is likely underestimated. The most prevalent TTR 
mutation is the peripheral-neuropathy associated TTRV30M variant. Moreover, it is 
estimated that approximately 4% of African Americans are carriers for the TTRV122I 
mutation, primarily associated with cardiomyopathy (i.e. TTR amyloid fibrils 
deposited in the cardiac tissue) (Buxbaum et al. 2017). Interestingly, the 
penetrance of certain mutations changes drastically depending on the patient’s 
ethnicity (Parman et al. 2016; Hellman et al. 2008). Penetrance of the peripheral 
neuropathy-associated TTRV30M mutation, for example, ranges from 18% of 
carriers developing the disease by age of 50 in France, to 80% by the age of 50 in 
Portugal (Parman et al. 2016; Hellman et al. 2008). At the same time, there 
appears to be correlations between inheritance pattern (i.e. paternal vs. maternal 
origin) and age-of-onset as well as sex of the patient (a majority of wild-type ATTR 
amyloidosis patients being male) (Buxbaum et al. 2008; Hellman et al. 2008). 
 In addition to variation in disease progression dependent upon ethnicity, a 
substantial amount of variability in clinical manifestation and responsiveness to 
treatments depends on the inherited mutation (Ando et al. 2016; Berk et al. 2013; 
Buxbaum 2019; Maurer et al. 2017; Maurer et al. 2018). This is largely due to the 
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relative stabilities of the natively folded monomer and/or tetramer conferred by the 
mutation. Highly destabilizing mutations such as TTRA25T and TTRL55P, for 
example, have a large propensity to misfold, and as a result, are less responsive 
to kinetic stabilizers which rely on physical interactions with the natively folded 
tetramer (McClutchen et al. 1993, Sekjima et al. 2003). This is contrasted to the 
relatively successful stabilization of homo- and heterotetramers composed of 
TTRWT or TTRV30M (Waddington Cruz and Benson 2015). 
Due to the multi-tissue etiology and highly aging-related component of the 
disease, ATTR amyloidosis has proven very difficult to study with traditional in vitro 
and in vivo models (Buxbaum 2009; Giadone et al. 2018; Leung et al. 2013; Leung 
and Murphy 2016). To this point, several mouse models of the disease have been 
developed; however, none currently recapitulates key aspects of ATTR 
amyloidosis pathogenesis (Buxbaum 2009). The earliest models, involving 
knocking-in human TTRV30M cDNA or genomic DNA (including upstream regulatory 
sequences), had no amyloid fibrils formed in the peripheral nerves (Buxbaum 
2009). Later mouse models, involving the introduction of a large number of 
genomic copies of wild-type and TTRL55P, achieve fibril deposition with 
approximately 100 copies of transgene (Buxbaum 2009). Curiously, upon 
transferring TTRV30M mice to a sterile facility, the mice no longer formed amyloid 
fibrils – implying an importance of the immune system in the formation of fibrils and 
disease (Buxbaum 2009; Inoue et al. 2008). 
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In addition to the limitations of ATTR amyloidosis mouse models for recapitulating 
disease phenotype, as noted above, the genetic background of the patient has 
strong effects on the progression of the disease (Ando et al. 2016; Berk et al. 2013; 
Buxbaum 2019; Maurer et al. 2017; Maurer et al. 2018). In order to address these 
observations, several groups now employ iPSCs to model the disease. In 2014, 
Leung et al. developed the first iPSC-based platform for studying hereditary ATTR 
amyloidosis (Figure 1.4). In the model, PBMCs are obtained from patients 
diagnosed with TTR amyloid disease and subsequently reprogrammed into iPSCs. 
Patient-specific iPSCs are then directed to differentiate into effector HLCs via a 
previously described two-dimensional, chemically-defined feeder-free directed 
differentiation protocol. Importantly, these HLCs secrete TTR variants which were 
then detected by proteomic methods (Giadone et al. 2018; Leung et al. 2013; 
Leung and Murphy 2016). At the same time, patient-matched iPSCs are then 
directed to differentiate into the target cells involved in the disease, including 
neuronal and cardiac cells. TTR-containing hepatic supernatant is subsequently 
generated and dosed onto iPSC-derived target cells and toxicity can be measured 
via flow cytometry cell death assays or expression of stress marker genes via qRT-
PCR. To this end, upon combining TTRL55P iPSC-derived hepatic supernatant with 
kinetic stabilizer diflunisal and subsequently dosing patient-matched iPSC-derived 
neuronal cells, toxicity in exposed neuronal cells decreases in the presence of the 
stabilizer compared to cells dosed with mutant supernatant in the absence of 
stabilizer (Figure 1.4) (Leung et al. 2013).  
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Figure 1.4 Multi-system iPSC-based modeling of hereditary ATTR 
amyloidosis recapitulates key aspects of human disease pathogenesis. 
Modified from Leung et al. 2013, the Murphy laboratory’s iPSC-based platform 
for modeling ATTR amyloidosis. (A) Schematic representation of model 
consisting of the reprogramming of patient-specific iPSCs and differentiation into 
hepatocyte-like, neuronal, and cardiac cells to measure responsiveness to TTR-
containing hepatic supernatant. (B) Flow cytometry-based, PI viability assay 
representing an increase in toxicity upon exposing iPSC-derived motor neurons 
to ATTR amyloidosis hepatic supernatant compared to cells dosed with wild-type 
control hepatic supernatant (40.5% dead/dying vs. 17.8%). Upon exposing motor 
neurons to ATTR amyloidosis hepatic supernatant with diflunisal, toxicity 
returned to levels comparable to wild-type control (12.6%).  Adapted from Leung 
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1.8 Summary  
Systemic amyloid disease is a class of highly complex disorders involving the 
production of proteins which misfold, travel throughout circulation, and deposit as 
proteotoxic aggregates at distal target organs. Although rare, the molecular and 
cellular mechanisms of these disorders are highly applicable to diverse aspects of 
biological dysfunction. Understanding mechanisms of multi-system protein folding 
disorders such as ATTR amyloidosis through iPSC-based platforms has the 
potential to lend novel insights into many aspects of protein misfolding, 
mistrafficking, and overall aging-related biological decline.    
As described in numerous exmaples above, iPSC-based models have lent 
great insight into the pathogenesis of many diverse, genetic diseases. This thesis 
describes the expansion of our laboratory’s previously described iPSC-based 
model for hereditary ATTR amyloidosis by generating a library of diverse patient-
derived iPSCs. With these tools, we test our central hypothesis that intracellular 
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    CHAPTER TWO. METHODS.   
Disclaimer: Portions of the text designated 2.1-2.7 below were adapted from the 
following publication: Giadone RM, Rosarda JD, Akepati PR, Thomas AC, 
Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, 
Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced 
pluripotent stem cells for disease modelling and in vitro testing of novel 
therapeutics. Amyloid. 2018;25(3):148-55. doi: 10.1080/13506129.2018.1489228 
[doi]. Portions of the text designated 2.8-2.17 were adapted from the following 
unpublished pre-print manuscript: Giadone RM, Liberti DC, Matte TM, Rosarda JD, 
Torres-Arancivia C, Ghosh S, Diedrich JK, Pankow P, Skvir N, Jean JC, Yates III, 
JR, Wilson AA, Connors LH, Kotton DN, Wiseman RL, Murphy GJ. Amyloidogenic 
proteins drive remodeling of hepatic proteostasis in an induced pluripotent stem 
cell model of systemic amyloid disease. 2019. bioRxiv. DOI: 
https://doi.org/10.1101/358515.   
 
2.1 Patient consent and global distribution of created lines.  
All of the iPSC lines in this bank were generated from patients using a progressive, 
state-of-the-art consent form. Informed consent for generation of iPSC lines 
derived from peripheral blood was obtained from all donor patients according to 
the Declaration of Helsinki. This consent form includes a comprehensive template 
that allows for the unrestricted sharing of created lines, including potential 
commercialization and sharing of lines with commercial entities. The described 
 
   31
library is available through the Boston University and Boston Medical Center’s 
Center for Regenerative Medicine ((CReM), http://www.bu.edu/dbin/stemcells/) via 
our “Open Source Biology” initiative. To capture the large phenotypic diversity of 
patients with ATTR amyloidosis, samples were procured from the Amyloidosis 
Center of Boston University School of Medicine. Reprogramming of material was 
performed on fresh samples immediately following collection or using frozen 
mononuclear cells that were previously collected and isolated from subjects. 
 
2.2 iPSC generation and maintenance.  
Derivation of our iPSC library was performed as described [Somers et al. 2010; 
Sommer et al. 2009; Sommer et al. 2012]. Briefly, 4 ml of peripheral blood was 
collected from all participating individuals and the mononuclear cells (either fresh 
or frozen) were expanded in vitro and reprogramed using the STEMCCA vector 
(Somers et al. 2010; Sommer et al. 2009; Sommer et al. 2012). At least, three 
independent clones were established, expanded and banked from each individual. 
For all studies described here, cells were maintained either on inactivated mouse 
embryo fibroblast (MEF) feeders with knockout serum replacement (KSR) 
supplemented media or under feeder-free conditions using mTeSRTM1 media 
(Somers et al. 2010; Sommer et al. 2009; Sommer et al. 2012). These studies were 
approved by the Institutional Review Board of Boston University. 
 
2.3 Immunostaining for pluripotency markers. 
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iPSCs were grown for 5 d prior to staining. Cells were fixed with 4% 
paraformaldehyde (PFA) in PBS for 20 min, permeabilized with 0.1% Triton X-100 
(Sigma, St. Louis, MO, Cat. No. T8787) in PBS for 10 min at room temperature, 
and subsequently blocked with 4% normal goat serum (Vector, San Diego, CA, 
Cat. No. S-1000) in PBS for 30 min. Primary antibodies (SSEA-1, SSEA-4, TRA-
1–60, and TRA-1–81, EMD Millipore, Billerica, MA, Cat. No. SCR001) were diluted 
1:25–1:50 in blocking solution and added to samples for 1 h. Secondary antibodies 
(Life Technologies, Carlsbad, CA, Cat. No. A21042; A11003) were diluted in PBS 
(1:100–1:250), and added to cells that were then incubated at room temperature 
for 30–60 min. Cells were stained with DAPI (Invitrogen, Carlsbad, CA, Cat. No. 
D1306) diluted in PBS (1:2000) and incubated for 5 min at room temperature. 
 
2.4 Directed differentiation of iPSCs to definitive endoderm and hepatocyte-
like cells. 
iPSCs were passaged with Gentle Cell Dissociation (GCD) Reagent (STEMCELL 
Technologies, Vancouver, Canada, Cat. No. 07174) to form a single-cell 
suspension and counted. Cells (2 x 106) were plated in one matrigel-coated well 
of a standard 6-well plate in mTeSR1 supplemented with Y-27632 (10 µM). 
Twenty-four hours later, media from the STEMdiff Definitive Endoderm Kit 
(STEMCELL Technologies, Vancouver, Canada, Cat. No. 05110) was added, and 
cells were cultured as per instructions for 4 days. On day 5, cells were passaged 
with GCD to obtain a single-cell suspension, and split 1:2 into matrigel-coated wells 
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of a standard 6-well plate. On days 5 and 6, cells were cultured in media 
containing: activin A (0.05 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 338-
AC), ascorbic acid (50 µg/mL) (Sigma-Aldrich, St. Louis, MO, Cat. No. A4544), 
BMP4 (0.01 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 314-BP), FGF2 
(0.01 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 233-FB), VEGF 
(0.01 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 293-VE), L-glutamine (Life 
Technologies, Carlsbad, CA, Cat. No. 25030-164), and monothioglycerol 
(4.5 × 10−4 M) (Sigma-Aldrich, St. Louis, MO, Cat. No. M6145) (Note: Day 5 media 
was supplemented with 10 μM Y-27632.). Hepatic specification continued for 
approximately 20 days in SFD-based media as previously described with medias 
specific for days 7–12, 13–18, and 19–26 (Wilson et al. 2015). Days 7–12 media 
contained: ascorbic acid (50 µg/mL), BMP4 (0.05 µg/mL), FGF2 (0.01 µg/mL), 
VEGF (0.01 µg/mL), EGF (0.01 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 
236-EG), TGFα (0.02 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 293-A), 
HGF (0.1 µg/mL) (R&D Systems, Minneapolis, MN, Cat. No. 294-HG), 
dexamethasone (0.1 µM) (Sigma-Aldrich, St. Louis, MO, Cat. No. D4902), L-
glutamine, and monothioglycerol (4.5 × 10−4 M). Day 13–18 media contained: 
ascorbic acid (50 µg/mL), FGF2 (0.01 µg/mL), VEGF (0.01 µg/mL), EGF 
(0.01 µg/mL), HGF (0.1 µg/mL), oncostatin M (0.02 µg/mL) (Life Technologies, 
Carlsbad, CA, Cat. No. PHC5015), vitamin K (6 µg/mL) (Sigma-Aldrich, St. Louis, 
MO, Cat. No. 47773), gamma secretase inhibitor (1.5 µM) (MilliporeSigma, 
Burlington, MA, Cat. No. 565771), DMSO (1%) (Sigma-Aldrich, St. Louis, MO, Cat. 
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No. D2650), dexamethasone (0.1 µM), L-glutamine, and monothioglycerol 
(4.5 × 10−4 M). Day 19–26 media contained: ascorbic acid (50 µg/mL), HGF 
(0.1 µg/mL), oncostatin M (0.02 µg/mL), vitamin K (6 µg/mL), dexamethasone 
(0.1 µM), L-glutamine, and monothioglycerol (4.5 × 10−4 M). For the entirety of the 
differentiation, cells were incubated at 37 °C, 5% O2, 5% CO2, and 90% N2. 
 
2.5 Characterization of definitive endoderm and hepatic markers. 
Flow cytometry was performed on days 5 and 26 of hepatic differentiation. On day 
5, cells were stained with antibodies specific for cell surface markers c-Kit 
(ThermoFisher, Waltham, MA, Cat. No. 17–1178-42) and C-X-C chemokine 
receptor 4 (CXCR4) (ThermoFisher, Waltham, MA, Cat. No. 12–9999-41). Five 
microlitre of each antibody were added to 5 × 105 cells. Staining was performed on 
ice for 30 min. For intracellular staining, on day 26, cells were fixed with 1.6% PFA 
(Ted Pella, Inc., Redding, CA, Cat. No. 18505) at 37 °C for 20 min. Primary 
antibodies for FOXA1 (Santa Cruz Technology, Santa Cruz, CA, Cat. No. 101058) 
and AAT (Santa Cruz Technology, Santa Cruz, CA, Cat. No. 59438) diluted 1:100 
in Saponin buffer (2% FBS, 1× Permeabilization Wash Buffer (Biolegend, San 
Diego, CA, Cat. No. 421002)) were added to cells and incubated for 30 min at room 
temperature. Secondary antibodies for FOXA1 (Jackson, West Grove, PA, Cat. 
No. 115–485-206) and AAT (Jackson West Grove, PA, Cat. No. 115–605-205), 
diluted 1:500 in Saponin buffer, were added to cells that were then incubated for 
30 min at room temperature. Samples were resuspended in 0.5% bovine serum 
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albumin (BSA) in PBS prior to flow cytometry analysis. Stained samples were 
subsequently analyzed via the FACSCalibur (BD Biosciences, Franklin Lakes, NJ). 
Gates were drawn based on unstained samples. 
 
2.6 RNA isolation, cDNA synthesis, and qRT-PCR. 
Total RNA was extracted from cells via RNeasy Mini Kit (Qiagen, Germantown, 
MD, Cat. No. 74104). RNA was eluted in 30 µL RNAse-free H2O. RNA was further 
purified via treatment with DNA removal kit (ThermoFisher, Waltham, MA, Cat. No. 
AM1906). One microgram purified RNA was used to generate cDNA via High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, 
Cat. No. 43–688-13). qRT-PCR was performed with TaqMan Universal Master Mix 
II, with UNG (ThermoFisher, Waltham, MA, Cat. No. 4440038). TaqMan Gene 
Expression Assays used include the following: β-actin (Hs99999903_m1), AAT 
(Hs00165475_m1), ALB (Hs00609411_m1), TTR (Hs00174914_m1), hepatocyte 
nuclear factor 4 alpha (HNF4A) (Hs00230853_m1), OCT4 (Hs00999634_gH), and 
alpha-fetoprotein (AFP) (Hs01040598_m1). Quantities of genes of interest were 
compared relative to β-actin levels. Fold-change was calculated via ΔΔCT method. 
Undetermined CT values were taken to be 40. Samples were run in triplicate. 
 
2.7 Mass spectrometric analysis of secreted TTR. 
TTR was immunoprecipitated from conditioned media prepared on iPSC-derived 
hepatic lineages using Protein A Sepharose 4B beads (Life Technologies, 
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Carlsbad, CA, Cat. No. 101041) cross-linked to TTR antibody (DAKO, Carlsbad, 
CA, Cat. No. A0002) using dimethyl pimeimidate (DMP; ThermoFisher, Waltham, 
MA, Cat. No. 21666) according to the manufacturer protocol. Conditioned media 
was incubated with cross-linked TTR-Sepharose 4B beads overnight at 4 °C. 
Beads were then washed four times in 0.05% Saponin, 10 mM Tris, 140 mM NaCl, 
pH 8.0 and twice in 10 mM Tris, 140 mM NaCl, pH 8.0 prior to elution. TTR was 
eluted from the beads by incubating resin at 95 °C for 10 min in an SDS-lysis buffer 
solution (2% SDS, 1% Triton X-100, HEPES 20 mM, EDTA 1 mM, NaCl 100 mM). 
Eluent was removed from beads, and 100 mM dithiothreitol (DTT) was added. The 
eluent was then incubated again at 95 °C for 5 min. Methanol precipitation was 
used to remove the detergent from eluent for subsequent LC/MS analysis. A 
mixture of methanol:chloroform:water (4:1:3) was added in proportion to the eluent 
volume. Samples were centrifuged at 21,800 × g for one minute and the aqueous 
layer was removed. Two additional methanol washes were performed to remove 
residual detergent. The sample was then centrifuged at 21,800 × g for 10 min to 
pellet the precipitated protein. The protein pellet was dried and resuspended in 
150 mM ammonium hydroxide pH 10.5. LC/MS analysis was performed on an 
Agilent single quadrupole mass spectrometer (Agilent Technologies, Palo Alto, 
CA), as previously described (Leung et al. 2013). All MS experiments were 
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2.8 Post-hoc microarray analysis.   
The heatmap and differential expression analysis was performed using data from 
Wilson et al. 2015. Differential expression between day 24 and day 0 of the hepatic 
differentiation was performed, resulting in 12,129 differentially expressed genes 
(FDR<0.05). The heatmap was generated using Ward's hierarchical clustering 
method on the row-scaled expression values of these genes (Murtagh and 
Legendre 2014).  
 
2.9 TALEN-mediated gene editing of patient-specific iPSCs.   
Briefly, iPSCs were cultured until ~60% confluent in a 6-well plate. Cells were 
transfected via Lipofectamine with PLUS reagent (ThermoFisher, Cat. Nos. 
11668019, 11514015). Cells were exposed to 1.2 µg of left and right TALEN 
targeting vectors and 3 µg of donor vector. Identification/selection of successfully 
transfected cells was performed by adding 700 ng/µL puromycin to cells. 
Puromycin cassette excision was accomplished using transient transfection of the 
pHAGE-EF1α-Cre-IRES-Neo plasmid followed by subsequent screening and 
single cell selection and expansion.  
 
2.10 Determining downstream neuronal toxicity in response to iPSC-derived 
HLC supernatant. 
Conditioned HLC supernatant was generated by incubating hepatic differentiation 
media on day 16 HLCs for 72 hours. Supernatant was collected and subsequently 
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concentrated using Centrifugal Filter Units (NMWL 10 kDa) (Millipore Sigma, Cat. 
No. UFC901024). (After first collection, cells were refed with media for an 
additional 72 hours to generate a second batch of conditioned supernatant.) 
Supernatant was first centrifuged at 200 x g for 1 minute at room temperature to 
remove cell debris. Media was then collected, transferred to filter units, and spun 
at 2140 x g for 45 minutes at room temperature. Concentrated supernatant was 
subsequently stored at 4ºC until dosing experiment. SH-SY5Y cells (ATCC, 
Manassas, VA, Cat. No. CRL-2266) were plated at 2x105 cells and subsequently 
dosed for ~7 days with media composed of SH-SY5Y growth media and 
conditioned supernatant at a 1:1 ratio. Media was replaced every 48 hours until 
toxicity assay was performed. After dosing cells, floating and adherent SH-SY5Y 
cells were collected, stained with PI (BD Biosciences, Cat. No. 556463), and 
analyzed via flow cytometry.  
 
2.11 Single-cell RNA sequencing and analysis.   
Corrected and uncorrected cells were sorted and entered into the Fluidigm C1 HT 
workflow, which was used to capture and lyse individual cells, reverse transcribe 
RNA, and prepare libraries for sequencing using the C1 High-Throughput IFC to 
Generate Single-Cell cDNA Libraries for mRNA Sequencing, Cat. No. 100-9886. 
Sequencing was performed on a Nextseq 500 using a high-output kit. This resulted 
in a total of 430 million paired-end, 75 bp reads. Reads were aligned to the human 
genome (GRCh38) and quantified using the STAR aligner (Dobin et al. 2013). 
 
   39
Outlier removal was performed (cells must have >1,500 genes detected, <3 
median absolute deviations away from median total reads, mitochondrial counts), 
in addition to removing a subpopulation determined through k-means clustering 
with high mitochondrial expression and low numbers of genes expressed. This 
resulted in 120 cells available for analysis, with a mean of 482,205 aligned 
reads/cell. Size factors were computed via the Scran Bioconductor package, which 
uses pool-based scaling factors and deconvolution, followed by log-transformation 
normalization using the Scater package (Lun et al. 2016). A one-way ANOVA was 
used to determine significantly (FDR<0.05) differentially expressed genes between 
corrected and uncorrected cells. Supervised PCA was performed using 
differentially expressed genes as factors. The heatmap was generated using 
Ward's hierarchical clustering method (Murtagh and Legendre 2014) on the row-
scaled expression values of differentially-expressed genes determined through the 
aforementioned method. Raw single-cell sequencing data can be accessed from 
the Gene Expression Omnibus at (GSE number pending).  
 
2.12 XBP1 splicing assay. 
RNA was isolated from HLCs and cDNA was generated via standard RT reaction 
(see above). XBP1 transcript was amplified via PCR reaction with forward primer 
5’- A AAC AGA GTA GCA GCT CAG ACT GC-3’ and reverse primer 5’- TC CTT 
CTG GGT AGA CCT CTG GGA G-3’. PCR program utilized included the following 
steps: 94ºC for 4 minutes, 35 cycles of 94ºC (10 seconds), 63ºC (30 seconds), and 
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72ºC (30 seconds), and lastly 72ºC for 10 minutes. Amplified transcripts were 
subsequently digested with PstI enzyme (New England BioLabs, Cat. No. R0140S) 
and analyzed on a 2.5% agarose gel. Relative quantities of bands were determined 
via ImageQuant TL software. For positive control for XBP1 activation, thapsigargin 
(Millipore Sigma, Cat. No. T9033) was added to undifferentiated iPSCs at a 
concentration of 1 µM for 24 hours.  
 
2.13 Recombinant expression and purification of TTRL55P.  
TTRL55P was expressed and purified as previously described (Kingsbury et al. 
2007). Briefly, TTRL55P was expressed in E. coli as an N-terminal histidine-tagged 
protein isolated from cell lysate after passage through Ni-NTA agarose (Qiagen, 
Cat. No. 30210). Bound TTRL55P was then eluted by competition with imidazole. 
Lastly, purified TTRL55P was loaded into an Econo-Pac 10DG desalting column 
(BIO-RAD, Cat. No. 7322010) for rapid buffer exchange to 10 mM sodium 
phosphate buffer pH 7.8, 100 mM KCl, 1 mM EDTA. The final concentration was 
adjusted to 0.4 mg/ml. Subsequently, purified TTRL55P was stored at 4°C and used 
within one week. All rhTTR experiments were done post-His-tag removal. 
 
2.14 In vitro fibril formation assay.   
TTRL55P fibril formation was triggered under mild acidic conditions. The amount of 
fibrils formed was measured by Congo red (CR) binding assay as reported 
previously (Klunk et al. 1989). TTRL55P and lyophilized human plasma-derived apo-
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transferrin protein (Apo-TF; R&D Sytems, Cat. No. 3188-AT) resuspended in 10 
mM sodium phosphate buffer (pH 7.8, 100 mM KCl, 1 mM EDTA) were both filtered 
through 0.2 µm membranes prior to their incorporation into the reaction mixtures. 
Addition of 50 mM sodium acetate buffer pH 4.6, 100 mM KCl lowered the pH of 
the reaction to 4.9. The final concentrations of TTRL55P and Apo-TF were 0.2 
mg/ml and 2500 µg/ml respectively. Fibril formation was carried out at 37°C without 
agitation in a mastercycler with lid temperature of 80°C to avoid condensation. 
Reactions were halted after 24 hours with the addition of 1.5 M Hepes pH 8.0. 
Finally, fibril formation reaction was added to 10 µM CR (Sigma-Aldrich, Cat. No. 
573-58-0) working dilution (prepared in 5 mM KH2PO4 pH 7.4, 150 mM NaCl). After 
15 minutes at room temperature, absorbance was taken at 477 nm and 540 nm. 
The amount of CR bound to amyloid fibrils was determined via molar concentration 
of bound CR= A540 nm/25295 – A477 nm/46306 (Klunk et al. 1989). The 








2.15 Generation of ATF6-inducible TTRL55P iPSC line.  
TTRL55P iPSCs were nucleofected (Lonza) with 3 µg of previously described 
DHFR.ATF6 donor construct (Shoulders et al. 2013) using the manufacturer’s 
protocol. After 48 hours of recovery post-nucleofection, cells were grown in 500 
ng/µL puromycin for approximately 10 days. Successfully grown colonies were 
subjected to dilution cloning to ensure clonality. To assess functionality, clonal, 
puromycin-resistant colonies were subjected to 10 µM TMP for 48 hours. RNA was 
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harvested from each clone and qRT-PCR was performed to assess upregulation 
of ATF6 target gene, HSPA5, in the presence of TMP. 
 
2.16 Tandem Mass Tag (TMT)–LC-MS/MS analysis of TTRWT and TTRL55P in 
conditioned media prepared on iPSC-derived hepatic lineages. 
Hepatic lineages were prepared from patient iPSCs expressing TTRWT and 
TTRL55P where TMP-regulated DHFR.ATF6 was introduced. Media was 
conditioned on these cells for 72 hours in the presence or absence of TMP (10 
µM). The media was collected and then subjected to chloroform/MeOH 
precipitation to precipitate proteins (Pankow et al. 2016). Dried pellets were 
dissolved in 8 M urea/100 mM TEAB, pH 8.5, reduced with 5 mM tris(2-
carboxyethyl) phosphine hydrochloride (TCEP), and alkylated with 50 mM 
chloroacetamide. Proteins were then dilute to 2 M urea/100 mM TEAB and trypsin 
digested overnight at 37°C. The digested peptides were labeled with TMT 
(ThermoFisher, Cat. No. 90309, Lot. No. UB274629). The TMT labeled samples 
were analyzed on a Orbitrap Fusion Tribrid mass spectrometer (ThermoFisher). 
Samples were injected directly onto a 30 cm, 100 μm ID column packed with BEH 
1.7 μm C18 resin (Waters). Samples were separated at a flow rate of 400 nL/min 
on a nLC 1200 (ThermoFisher). Buffer A and B were 0.1% formic acid in 5% 
acetonitrile and 80% acetonitrile, respectively. A gradient of 1–30% B over 160 
min, an increase to 90% B over 60 min and held at 90% B for 20 minutes was used 
for a 240 minute total run time. Column was re-equilibrated with 20 μL of buffer A 
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prior to the injection of sample. Peptides were eluted directly from the tip of the 
column and nanosprayed directly into the mass spectrometer by application of 2.8 
kV voltage at the back of the column. The Orbitrap Fusion was operated in a data 
dependent mode. Full MS1 scans were collected in the Orbitrap at 120k resolution. 
The cycle time was set to 3 s, and within this 3 s the most abundant ions per scan 
were selected for CID MS/MS in the ion trap. MS3 analysis with multinotch isolation 
(SPS3) was utilized for detection of TMT reporter ions at 30k resolution (McAlister 
et al. 2014). Monoisotopic precursor selection was enabled and dynamic exclusion 
was used with exclusion duration of 10 seconds. 
Protein and peptide identification were done with Integrated Proteomics 
Pipeline – IP2 (Integrated Proteomics Applications). Tandem mass spectra were 
extracted from raw files using RawConverter (He et al. 2015) and searched with 
ProLuCID (Xu et al. 2015) against Uniprot human database. The search space 
included all fully-tryptic and half-tryptic peptide candidates. Carbamidomethylation 
on cysteine and TMT labels on N terminus and lysine were considered as static 
modifications. Data was searched with 50 ppm precursor ion tolerance and 600 
ppm fragment ion tolerance. Identified proteins were filtered to 10 ppm precursor 
ion tolerance using DTASelect (Tabb et al. 2002) and utilizing a target-decoy 
database search strategy to control the false discovery rate to 1% at the protein 
level (Peng et al. 2003). Quantitative analysis was done with Census (Park et al. 
2014) filtering reporter ions with 20 ppm mass tolerance and 0.6 isobaric purity 
filter.   
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 Peptide quantifications corresponding to the 
TSESGEL/PHGLTTEEEFVEGIYKVEIDTK peptide from TTRWT or TTRL55P 
were initially analyzed for each biological replicate. Peptides showing a m/z signal 
less than 10,000 were excluded from the analysis. A TMP ratio for each identified 
peptide was quantified using the following equation: TMP ratio = peptide signal in 
+TMP channel replicate = n / peptide signal –TMP channel replicate = n. The TMP 
ratio for individual peptides was then averaged across all peptides observed for 
each individual biological replicate to generate the plots shown in Figure 4.8. The 
relative impact of TMP on the secretion of TTRL55P was then quantified by 
normalizing the average TMP ratio for the TTRL55P peptide to the TMP ratio for the 
TTRWT peptide to generate the plot shown in Fig. 5D.    
 
2.17 Morphological assessment of the impact of ATF6 signaling on HLCs 
exposed to prolonged ER stress. 
To assess morphological differences under severe, prolonged stress, iPSC-
derived HLCs were dosed with 50 nM thapsigargin for 5 days beginning on day 15 
of the differentiation. In stressed cells with ATF6 activation, TMP was 
simultaneously added at a concentration of 10 µM. In instances where ATF6 
signaling was inhibited in the presence of thapsigargin, 6 µM Ceapin-A7 (CP7) 
(Sigma-Aldrich, Cat. No. SML2330) was added to cells. After dosing for 5 days, 
cell morphology was noted. To account for degradation, the above additives 
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(thapsigargin, TMP, and CP7) were supplemented to media at half-concentration 
every other day. 
 
2.18 Quantifying protein concentration via Bradford assay. 
Concentration of rhTTRs was determined via Bradford assay. Samples were 
thawed on ice and diluted 1:1000 in 1X Bradford reagent (Cat. No. 500-0006, 
BioRad). Standard curve was determined via serial dilutions of 1 mg/mL BSA 
diluted in H2O. All samples including standards were incubated at room 
temperature for ~10 minutes. Absorbance was determined at 595 nm. All samples 
(including standards) were ran in technical duplicate.  
 
2.19 Annexin V-PI staining flow cytometry-based cell death assay.  
Cells were harvested utilizing 0.05% trypsin at 37ºC for 2.5 - 5 minutes (incubation 
time dependent on cell type). Trypsin was inactivated by adding FBS-containing 
media. Cells were counted and 1x105 were centrifuged at 300 x g for 5 minutes 
and resuspended in 100 µL 1X binding buffer (composition). Per manufacturer’s 
protocol, 5 µL annexin V (ThermoFisher, Waltham, MA, Cat. No. V13242) and 1 
µL PI were added to each sample. Samples were covered and incubated on ice 
for 15 minutes. 400 µL 1X binding buffer was added, cells were subjected to a 40 
µm filter, and analyzed via flow cytometry.  
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2.20 Stress conditions for cells: thapsigargin, recombinant TTR exposure, 
and NaAsO2. 
For thapsigargin exposure, cells were plated at 2x105 cells/mL. 24 hours later, cells 
were exposed to 500 nM thapsigargin for 20 hours, and harvested as previously 
stated. For rhTTR exposure for transcriptomic profiling, cells were plated at 2x105 
cells/mL. 24 hours later, 0.0125 mg/mL respective recombinant protein in the 
absence and presence of 10 µM tafamidis were added. After incubating cells at 
37ºC for 48 hours, cells were harvested for either RNA extraction or flow cytometry.  
 
2.21 Culturing SH-SY5Y, HepG2, and AC16 cells. 
SH-SY5Y cells (ATCC, Manassas, VA, Cat. No. CRL-2266, ATCC) were 
maintained in 1:1 EMEM and DMEM F/12 with 10% FBS. HepG2 (ATCC, 
Manassas, Cat. No. HB-8065,) cells were grown in EMEM with 10% FBS. AC16 
cells (MilliporeSigma, Burlington, MA, Cat. No. SCC109)  were cultured in 
DMEM/F12 with 12.5% FBS. All cells were maintained at 37ºC and 5% CO2 and 
grown in media supplemented with 1X primocin (REPROCELL, Boston, MA, Cat. 
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CHAPTER THREE. A LIBRARY OF ATTR AMYLOIDOSIS PATIENT-SPECIFIC 
INDUCED PLURIPOTENT STEM CELLS FOR DISEASE MODELLING AND IN 
VITRO TESTING OF NOVEL THERAPEUTICS. 
Disclaimer: Data and portions of the text in this chapter were originally published 
as: Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, 
Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A 
library of ATTR amyloidosis patient-specific induced pluripotent stem cells for 
disease modelling and in vitro testing of novel therapeutics. Amyloid. 
2018;25(3):148-55. doi: 10.1080/13506129.2018.1489228 [doi]. RMG conceived 
of the project, wrote the manuscript, and conducted experiments. JDR performed 
MS experiments. PRA performed intracellular flow cytometry. ACT performed 
immunostaining. LHC assisted in editing the manuscript. GJM conceived of the 
project and edited the manuscript. 
 
3.1 Introduction  
Hereditary transthyretin amyloidosis (ATTR amyloidosis) is an autosomal 
dominant protein folding disorder that results from over 100 described mutations 
in the transthyretin (TTR) gene. In the disease, TTR tetramers secreted by the 
liver, can dissociate to monomers, misfold and oligomerize into proteotoxic fibrils 
that deposit as amyloid at downstream target tissues (e.g. the peripheral nervous 
system and/or cardiac tissue), inducing cell death (Blancas-Mejia and Ramirez-
Alvarado 2013). Current therapies for ATTR amyloidosis include orthotopic liver 
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transplantation, small molecule TTR tetramer stabilizers (e.g. diflunisal or 
tafamidis), and small interfering RNA species (siRNAs). Conventional therapeutics 
rarely succeed in preventing ATTR amyloidosis disease progression due to 
continued formation of wild-type TTR fibrils after liver transplantation or variable 
and unpredictable tetramer response to different treatments (Ando et al. 2016; 
Berk et al. 2013; Butler et al. 2016; Maurer et al. 2017). Alternative strategies are 
needed to combat systemic amyloid diseases such as ATTR amyloidosis. 
Patients with ATTR amyloidosis present with a wide degree of phenotypic 
manifestations. Some mutations preferentially affect one organ system. For 
example, patients with the V122I mutation primarily exhibit cardiomyopathy, while 
those with the leucine-to-proline at position 55 (L55P) or valine-to-methionine at 
position 30 (V30M) variant present with polyneuropathy (Dungu et al. 2012: 
Lashuel et al. 1999). Interestingly, the same mutation can present with different 
pathologies in different individuals. The average age of onset for V30M, the most 
prevalent disease-causing mutation, varies greatly across different geographic 
locations – 33 years of age in Portugal and Japan compared with 56 years in 
Sweden (Hellman et al. 2008). Similarly, in Portugal, the penetrance of the V30M 
mutation is as high as 80% by the age of 50, but only 5–10% in Swedish carriers 
(Parman et al. 2016). The highly variable genetics of the disease, especially in the 
context of patients with the same mutation, suggests severely underappreciated 
genetic modifiers that could alter disease progression. To properly understand 
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ATTR amyloidosis pathogenesis and develop novel therapeutics, disease models 
must consider the genetic backgrounds of patients. 
Due to the multi-organ and age-related nature of disease, ATTR 
amyloidosis proves difficult to study in a feasible and biologically relevant way. To 
date, no mouse model accurately recapitulates human ATTR amyloidosis 
pathology, while bacteria-derived recombinant TTR lacks seminal post-
translational modifications implicated in TTR function and disease pathogenesis 
(Buxbaum 2009; Henze et al. 2015; Vilà-rico et al. 2015).  
Described above, our iPSC-based model of ATTR amyloidosis allows us to 
study the pathogenesis of the disease in the genetic background of the patient,  
(Leung et al. 2014). In this model, patient-specific iPSCs are directed to 
differentiate into “effector” cells (hepatocyte-like cells, HLCs) by the serial addition 
of a number of chemically defined cytokine cocktails. Importantly, HLCs secrete 
wild-type and destabilized TTR variants, detectable by mass spectrometry (MS). 
In parallel, patient-matched iPSCs can be differentiated into “target organ” cell 
types – cardiomyocytes and neuronal cells. Conditioned media generated from 
HLCs can be used to dose target cells and downstream toxicity can be evaluated, 
thereby recapitulating key causative aspects of ATTR amyloidosis disease etiology 
including cardiotoxicity and neurotoxicity. 
In order to further develop and expand our iPSC-based model, we describe 
the characterization of six representative iPSC lines from a library of iPSCs and 
reprogrammable blood samples from ATTR amyloidosis patients. These iPSC 
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lines are genetically identical to the individual from whom they are derived, allowing 
for disease modelling and the development of novel therapeutics in the exact 
genetic context of the patient. This unique resource can be used in combination 
with our laboratory’s cell-based model (Leung et al. 2014) to facilitate studies into 
the genetic and epigenetic factors of the disease – including the effects of 
intracellular production and exposure to diverse, destabilized TTRs.  
 
3.2 Establishment of an ATTR amyloidosis disease-specific iPSC library 
representing multiple TTR mutations and target tissue pathology 
Unless otherwise stated, peripheral blood samples were procured from patients 
seen at the Amyloidosis Center at Boston University and Boston Medical Center 
in an effort to obtain a wide representation of mutations and associated disease 
phenotypes. This starting material was used to generate more than 30 
independent iPSC lines from individuals of African-American, Caucasian, and 
Asian descent (Table 3.1). Three independent clones were generated from each 
patient, with starting samples representative of both genders and a wide range of 
ages (16–65 years old). All lines were created using previously described 
methodologies and met stringent quality control parameters for pluripotency and 
functionality (Figure 3.1) (Somers et al. 2010; Sommer et al. 2009; Sommer et al. 
2012). Most lines in the library have been adapted to grow under feeder-free 
conditions. Here, we describe the characterization of six representative patient-
specific iPSC lines from the abovementioned library. 
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3.3 Characterization of capacity for directed differentiation into the hepatic 
lineage 
Differentiation capacity characterization of banked lines was performed as we 
previously described using a step-wise, 2D, feeder-free, and chemically defined 
hepatic specification protocol (Figure 3.2) (Wilson et al. 2015). Upon initial 
specification to definitive endoderm, the majority of iPSC-derived cells exhibited 
robust co-expression of the key markers of this developmental stage, CXCR4 and 
c-KIT (Figure 3.3). Upon further differentiation into HLCs, qRT-PCR analyses 
demonstrated marked upregulation of hepatic marker genes albumin (ALB), TTR, 
AFP, HNF4A, and AAT accompanied by downregulation of the pluripotency marker 
OCT4 (Figure 3.4A). Day 26 HLCs also exhibited protein-level co-expression of 
intracellular hepatic markers AFP and FOXA1, by flow cytometry (Figure 3.4B). 
Additionally, iPSC-derived HLCs exhibited limited protein expression of the late-
stage hepatic marker, ALB (Figure 3.5). The ability of iPSC-derived HLCs to 
achieve robust expression of adult-type markers such as ALB has not yet been 
achieved in directed differentiation protocols (Baxter et al. 2015). Disparities were 
noted between transcript and protein level expression of ALB (Figures 3.4A and 
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Table 3.1 Clinical data for six representative iPSC lines from a bank of over 
30 independent patient samples.   
Lines characterized herein represent patients of different genetic backgrounds and 
ethnicities. Patients from which lines were established exhibit various 
symptomatology (e.g., target organ affected) and severity (age of onset). M: male; 
F: female; Dx: diagnosis; Abd. fat – Congo red results: presence or absence of 
Congo red positive fibrils in abdominal fat biopsies; NA: not applicable; ND: not 
determined, –: unknown; Con’d: treatment was continued on subsequent visits. 
TTRL55P iPSCs were generated via reprogramming commercially available patient 
fibroblasts (ATCC, Manassas, VA). Multiple entries include data from follow-up 
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Figure 3.1 Patient-specific iPSCs express hallmark pluripotency markers. 
Five days after passaging, iPSC colonies from all representative lines express 
hallmark pluripotency cell surface markers TRA-1–60, TRA-1–81, and SSEA4. 
Colonies do not express murine pluripotent stem cell surface marker SSEA1. 
Nuclei stain blue with DAPI. Images taken at 10X magnification. Adapted from 
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Figure 3.2 Feeder-free, chemically defined differentiation protocol for 
generating hepatocyte-like cells (HLCs) from patient-specific iPSCs.  
Schematic depicts representative photomicrographs at multiple stages of hepatic 
differentiation. Cytokines included at each stage of the differentiation process are 
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Figure 3.3 Robust generation of definitive endoderm cells from patient-
specific iPSCs.  
After five days of directing iPSCs toward definitive endoderm, the majority of cells 
exhibit robust co-expression of the key markers of this developmental stage, 
CXCR4 and c-Kit. Undifferentiated cells (right) express c-Kit, but not CXCR4. 
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3.4 iPSC-derived HLCs secrete wild-type and variant-specific destabilized 
TTR species  
In order to assess the potential of iPSC-derived HLCs to secrete both normal and 
amyloidogenic TTR, we employed LC/MS characterization of conditioned media 
prepared on HLCs (Figure 3.6A–E). These analyses demonstrated recovery of 
both wild-type (WT) TTR and ATTR amyloidosis disease-specific mutant forms of 
TTR. Interestingly, in most cases, the relative recovery of WT species was greater 
than that of the disease-specific variant (Figure 3.6F). 
 
3.5 Summary and conclusions 
We have generated a library of iPSCs from patients with hereditary transthyretin 
amyloidosis, representing multiple TTR mutations and target tissue pathology for 
applications related to disease modelling and drug discovery. These fully 
characterized lines, along with accompanying functional data are now freely 
available, providing a resource to aid in the understanding of the complex etiology 
of the disorder.   
Drug development is an extremely expensive and time-consuming process 
that requires stringent specificity, potency, and toxicity validation of potential novel 
therapeutics. If in vitro testing is performed on human cells prior to clinical trials, 
these cells are typically immortalized cell lines, which have undergone genetic 
alterations to ensure their immortalization, possibly compromising the fidelity of 
drug screens. 
 
   57
 
Figure 3.4 iPSC-derived HLCs upregulate hallmark hepatic markers and 
downregulate pluripotency markers.  
(A) On day 26 of hepatic differentiation to HLCs, qRT-PCR analyses demonstrate 
marked upregulation of hepatic marker genes ALB, TTR, AFP, HNF4A, and alpha-
1 antitrypsin (AAT) accompanied by downregulation of the pluripotency 
marker OCT4. Human fetal and adult liver controls are included for comparison 
(n=3 individual differentiations of same iPSC line/clone)., (B) Day 26, HLCs exhibit 
protein-level expression of intracellular hepatic markers AFP and FOXA1 by flow 
cytometry. Adapted from Giadone et al. 2018. 
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Figure 3.5 HLCs exhibit protein level expression of late-stage liver marker, 
albumin. 
On day 26 of differentiation, patient-specific iPSC-derived HLCs exhibit modest 
protein-level expression of late-stage liver marker albumin by intracellular FACS. 
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Figure 3.6 LC/MS characterization of TTR mutants secreted from HLCs. 
(A-E) LC/MS deconvolution spectra showing recovery of WT TTR (black) or 
specific TTR mutant (red) from TTR IPs of conditioned media prepared on iPSC-
derived HLCs. A +48 peak was observed in some TTR IPs for both WT and mutant 
variants, reflecting oxidation of TTR. The mass of each mutant is shown, while the 
mass of WT TTR was determined to be 13761 +/− 2 Da. Grey peaks observed in 
(A) and (C) likely depict a doubly oxidized TTR species and unidentified species 
of negligible abundance, respectively. (Note: Bovine TTR (13555) was detected in 
these experiments, but we omitted this peak from the above spectra for clarity.) (F) 
Bar graph showing the relative recovery of mutant TTR compared to WT TTR (red 
and grey bars, respectively) in the IPs shown in panels A-E. The relative recovery 
of oxidized mutant TTR relative to oxidized WT TTR showed similar recoveries, 
but are not included here. Adapted from Giadone et al. 2018. 
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The use of immortalized cells lines is a common cause of high attrition rates for 
drug development, as in vitro and subsequent animal model data may not predict 
clinical effect (Kola and Landis 2004). IPSCs provide a novel way to 
mechanistically assess disease ontogeny as well as to obtain drug-related toxicity 
and efficacy data in multiple cell types from the same individual, before human 
clinical trials (Chun et al. 2011; Deshmukh et al. 2012; Lian et al. 2010). As 
discussed in Chapter 1, iPSCs have been used to model diseases as well as 
screen drugs for the treatment of amyotrophic lateral sclerosis, spinal muscular 
atrophy, long QT syndrome, and familial dysautonomia, thus initiating iPSCs into 
the drug discovery phase of therapeutic development (Ebert et al. 2009; Egawa et 
al. 2012; Itzhaki et al. 2011; Lee et al. 2009). 
ATTR amyloidosis is phenotypically diverse, a quality that arises from the 
many causal mutations in combination with variable genetic backgrounds in the 
diverse patient population that suffers from the disorder. Since there are still many 
unknown regulators of TTR expression and exposure, finding drugs that will be 
efficacious in patients with a variety of genetic backgrounds would be ideal. The 
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CHAPTER FOUR. AMYLOIDOGENIC PROTEINS DRIVE HEPATIC 
PROTEOSTASIS REMODELING IN AN INDUCED PLURIPOTENT STEM 
CELL MODEL OF SYSTEMIC AMYLOID DISEASE. 
Disclaimer: Data and portions of the text in this chapter were submitted in the form 
of the following pre-print manuscript: Giadone RM, Liberti DC, Matte TM, Rosarda 
JD, Torres-Arancivia C, Ghosh S, Diedrich JK, Pankow P, Skvir N, Jean JC, Yates 
III, JR, Wilson AA, Connors LH, Kotton DN, Wiseman RL, Murphy GJ. 
Amyloidogenic proteins drive remodeling of hepatic proteostasis in an induced 
pluripotent stem cell model of systemic amyloid disease. 2019. bioRxiv. DOI: 
https://doi.org/10.1101/358515. RMG conceived of the project, wrote the 
manuscript, and conducted experiments. DCL and JCJ performed gene correction. 
JDR performed MS experiments. TMM assisted with scRNAseq experiment and 
performed bioinformatics analysis. DNK and RLW edited the manuscript. GJM 
conceived of the project and edited the manuscript.  
 
4.1 Introduction 
Systemic amyloid disease represents a class of devastating protein folding 
disorders affecting over 1 million individuals worldwide (Blancas-Mejia and 
Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 1997; Merlini and Westermark 
2004; Wechalekar et al. 2016). In these diseases, proteins containing destabilizing 
mutations are produced and secreted from an effector organ into circulation. In the 
blood, these proteins undergo misfolding and subsequent aggregation into toxic 
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oligomers and amyloid fibrils, which deposit at distal target organs resulting in 
cellular death and organ dysfunction. Systemic amyloid diseases can result from 
the pathogenic misfolding of over 30 structurally distinct proteins, a majority of 
which are synthesized by the liver (Benson et al. 2018). A prominent example of 
this family of diseases is hereditary transthyretin amyloidosis (ATTR amyloidosis).  
Hereditary ATTR amyloidosis is a complex autosomal dominant disorder 
that can result from over 100 mutations in the transthyretin (TTR) gene (Ando et 
al. 2005; Benson 2012; Reixach et al. 2004; Ruberg and Berk 2012). In normal 
conditions, TTR is produced chiefly by the liver, where it forms a homotetramer 
and is then secreted, allowing for the transport of thyroxine and retinol binding 
protein throughout circulation (Ando et al. 2005; Benson 2012; Reixach et al. 2004; 
Ruberg and Berk 2012). In patients with ATTR amyloidosis, TTR mutations 
decrease the stability of the tetramer and result in monomerization and subsequent 
misfolding of TTR variants. Amyloid-prone monomers then aggregate to form 
proteotoxic low-molecular weight oligomers and eventually hallmark congophilic 
amyloid fibrils at downstream target tissues including the heart and peripheral 
nerves (Ando et al. 2005; Benson 2012; Reixach et al. 2004; Ruberg and Berk 
2012). Current standards of care for patients with the disease include small 
molecule kinetic stabilizers tafamidis and diflunisal, which work to stabilize the 
tetrameric protein and limit monomerization and downstream fibril formation (Ando 
et al. 2016; Berk et al. 2013; Gertz et al. 2015; Maurer et al. 2017; Maurer et al. 
2018). Despite some success in clinical trials for both compounds and FDA 
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approval for the use of tafamidis in the treatment of TTR-related cardiomyopathy, 
not all patients respond equally and effectively to these medicines. This can be 
attributed to the inherited deleterious TTR mutation as well as the underlying 
genetic background of the individual (Ando et al. 2016; Berk et al. 2013; Buxbaum 
2019; Gertz et al. 2015; Maurer et al. 2017; Maurer et al. 2018). Due to their multi-
tissue etiologies and age-related trajectories, systemic amyloid diseases like 
ATTR amyloidosis have proven difficult to study in a physiologically-relevant way. 
At the same time, no mouse model currently recapitulates key aspects of human 
TTR amyloid pathology (Buxbaum 2009; Giadone et al. 2018; Leung et al. 2013; 
Leung and Murphy 2016; Sousa et al. 2002). To better understand disease 
pathogenesis in the genetic context of affected patients, we leveraged our 
previously described, patient-specific induced pluripotent stem cell (iPSC)-based 
model for studying the disease. In this system, TTR amyloid disease-specific 
iPSCs are differentiated into effector hepatocyte-like cells (HLCs) that produce and 
secrete destabilized, amyloidogenic mutant TTR that can then be used to dose a 
myriad of iPSC-derived, disease-associated target cells (Giadone et al. 2018; 
Leung et al. 2013; Leung and Murphy 2016).  
Traditionally, the livers of ATTR amyloidosis patients have been thought to 
be unaffected throughout disease pathogenesis, as toxicity occurs at downstream 
target organs such as the heart and peripheral nerves (Ando et al. 2005; Benson 
2012; Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 
1997; Merlini and Westermark 2004; Reixach et al. 2004; Ruberg and Berk 2012; 
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Wechalekar et al. 2016). Despite this however, recent studies suggest the capacity 
for the liver to contribute to the deposition of amyloidogenic proteins at distal target 
tissues. In line with this, recipients of domino liver transplantations (DLTs), where 
an individual in end-stage liver failure receives a liver from an ATTR amyloidosis 
patient, show accelerated TTR amyloid disease pathogenesis, wherein TTR fibrils 
accumulate on target organs in fewer than 10 years (Ericzon 2007; Llado et al. 
2010; Misumi et al. 2016; Muchtar et al. 2017; Stangou et al. 2005; Yamamoto et 
al. 2007). Furthermore, in vivo mouse experiments have shown that the deposition 
of TTR on the hearts of old mice correlates with altered expression of numerous 
genes in the liver associated with the regulation of hepatic proteostasis (Buxbaum 
et al. 2012). Together, these results implicate the liver in the pathogenesis of 
systemic amyloid diseases such as ATTR amyloidosis. Despite these observations 
however, the molecular and cellular changes in the liver that contribute to the toxic 
aggregation of misfolded TTR in distal tissues remains unclear. 
Here, we utilize our laboratory’s previously described patient-specific iPSC-
based model of ATTR amyloidosis to investigate the contribution of proteostasis 
and hepatic disease modifying factors to the distal toxicity observed in patients 
with the disease. Recent attempts have been made to identify transcriptional 
differences between ATTR amyloidosis and wild-type iPSC-derived HLCs via bulk 
transcriptomic methodologies (Niemietz et al. 2018). Problematically, the 
maturational status of examined cells in these studies was considered and 
reported results likely reflect distinct differentiation efficiencies between lines. As a 
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result, differences in human ATTR amyloidosis hepatic cells resulting solely from 
TTR mutations remain elusive. By utilizing gene editing in combination with single 
cell RNA sequencing (scRNAseq) however, we define distinct transcriptional 
profiles in syngeneic corrected and uncorrected ATTR amyloidosis iPSC-derived 
HLCs that correlate with expression of a destabilized, amyloidogenic TTR variant. 
Through these efforts, we show that expression of the most proteotoxic, disease-
associated TTR mutant in HLCs increases expression of genes and pathways 
inversely implicated in the toxic extracellular aggregation of TTR, including 
transferrin and UPR target genes. To assess the consequence of functional 
activation of adaptive UPR signaling within hepatic cells expressing mutant TTR, 
we generated an ATF6-inducible patient-specific iPSC line. We further utilize this 
tool to demonstrate that exogenous ATF6 activation preferentially reduces the 
secretion of mutant, amyloidogenic TTR relative to the wild-type protein.  
Herein, we demonstrate that hepatic expression of amyloidogenic TTR 
results in differential expression of proteostasis factors known to protect the 
extracellular space from toxic protein aggregation. 
 
4.2 TTR is a top differentially expressed gene throughout human hepatic 
specification 
Recent work from our group demonstrated the emergence of a stage-dependent 
disease signature of hepatic-specified pluripotent stem cells (PSCs) (Wilson et al. 
2015). In these experiments, microarray analyses were performed on cells isolated 
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at days 0, 5, and 24 of hepatic differentiation. Post-hoc analysis of this data 
revealed that TTR was the second most differentially expressed gene comparing 
differentiated HLCs to PSCs (Figure 4.1A). To confirm this, qRT-PCR was 
performed on RNA isolated from day 24 HLCs, demonstrating significant 
upregulation of TTR as compared to undifferentiated iPSCs (Figure 4.1B). These 
data demonstrate that TTR is a robust marker of hepatic specification and can be 
used to normalize stem cell-derived hepatic differentiations.   
 
4.3 Gene editing of ATTR amyloidosis iPSCs eliminates secretion of mutant 
TTRL55P and decreases target cell toxicity  
As noted above, TTR is one of the most differentially expressed genes in HLC 
differentiation, suggesting it might serve as an excellent candidate locus to target 
and generate a hepatic specification reporter iPSC line. To this end, we employed 
TALEN-mediated gene editing to manipulate an iPSC line derived from a patient 
with the Leu55 →Pro (TTRL55P) mutation, the most proteotoxic disease-causing 
variant (Lashuel et al. 1999; McCutchen et al. 1993). In order to implement a 
broadly applicable gene correction strategy, we targeted the ATG start site of the 
endogenous, mutant TTR allele, introducing a normal TTR coding sequence, 
followed by a 2A self-cleaving peptide and eGFP coding sequence (Figure 4.1C). 
Inclusion of a 2A peptide allows for transcription of a single mRNA that ultimately 
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Figure 4.1 Creation of a TTR promoter-driven hepatic specification reporter 
iPSC line and universal gene editing strategy for hereditary ATTR 
amyloidosis. 
(A) Undifferentiated PSCs and day 24 HLCs (green and yellow columns, 
respectively) form distinct, independent clusters by microarray analysis. Top 10 
transcripts upregulated in HLCs are labeled on the y-axis, highlighted by green 
box. Top 10 transcripts downregulated in HLCs are labeled on the y-axis (below). 
Top differentially expressed genes were determined by one-way ANOVA. (B) qRT-
PCR validating microarray finding that expression of TTR mRNA is significantly 
upregulated in day 24 HLCs compared to undifferentiated iPSCs; fold-change 
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Figure 4.1 Creation of a TTR promoter-driven hepatic specificati n reporter 
iPSC line and universal gene editing strategy for hereditary ATTR 
amyloidosis. 
(A) Undifferentiated PSCs and day 24 HLCs (green and yellow columns, 
respectively) form distinct, independent clusters by microarray analysis. Top 10 
transcripts upregulated in HLCs are labeled on the y-axis, highlighted by green 
box. Top 10 transcripts downregulated in HLCs are labeled on the y-axis (below). 
Top differe tially expressed genes were determined by one-way ANOVA. (B) qRT-
PCR vali ating microarray finding that expression of TTR mRNA is si nificantly 
upregulated in day 24 HLCs compared to undifferentiated iPSCs; fold-change 
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calculated over undifferentiated iPSCs (n=3, *p<0.05, unpaired t-test for 
significance, bars denote standard deviation). (C) Schematic representation of the 
gene targeting strategy. Black triangles flank Cre-excisable LoxP sites. (D) Flow 
cytometry-based time course of GFP+ cells that appear throughout hepatic 
specification of targeted iPSCs (n=3, bars denote standard deviation, GFP+ cells 
determined based off of baseline fluorescence levels observed in non-targeted 
iPSC-derived HLCs). (E) Phase (left) and fluorescence (middle, right) microscopy 
images of day 26 reporter iPSC-derived HLCs. Images taken at 20X magnification. 
(F) Expression of hepatic markers in sorted day 16 GFP+ HLCs; fold-change 
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As a result of this targeting methodology, transcription and translation of mutant 
TTR is abrogated via introduction of an artificial STOP codon and polyA sequence, 
and replaced with a normal TTR coding sequence (Figure 4.1C). Importantly, this 
universal gene correction strategy provides a singular technique for correcting all 
known TTR genetic lesions while simultaneously obviating concerns regarding 
haploinsufficiency via replacement of the endogenous mutant TTR allele with a 
wild-type copy. (Additional information regarding generation and characterization 
of corrected iPSCs can be found in Figure 4.2.) 
 Using this TTR reporter line, we then measured the kinetics of GFP 
expression throughout HLC differentiation by flow cytometry. In doing so, we found 
that expression of GFP peaked at approximately day 16 of a 24-day specification 
protocol (Figure 4.1D). By day 24 of the differentiation, HLCs exhibited 
cobblestone-like morphology, and the majority of cells expressed GFP (Figure 
4.1E). To further validate this reporter line and ensure that GFP expression 
correlated with the expression of TTR as well as other hepatic-specification 
markers, day 16 GFP+ HLCs were sorted and assayed via qRT-PCR. GFP+ cells 
expressed high levels of TTR, as well as other hepatic specification markers such 
as AAT and ALB (Figure 4.1F), suggesting that our corrected reporter cell line 
labels maturing hepatic-lineage cells during specification.      
We further examined the ability of this strategy to eliminate the production 
of destabilized, disease-causing TTR, as well as alleviate downstream toxicity 
(Figure 4.3A). 
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Figure 4.2 Validation of targeted iPSC reporter line for site-specific 
integration of transgene as well as karyotypic stability.  
(A) Targeting construct used to perform gene correction. Red arrows denote the 
forward primer utilized for allele integration and puromycin cassette excision 
assay. Blue arrow represents the reverse primer used in the targeted integration 
screen. Green arrow depicts the reverse primer utilized for puromycin resistance 
(puroR) cassette excision. (B) PCR screen of gDNA for targeted integration of 
donor construct (left) and excision of puroR cassette (right). Arrows below gels 
denote where PCR primers bind within the donor construct/targeted locus (listed 
in panel A). (C) Non-targeted (left) and corrected (right) TTRL55P iPSCs derived 
from a female ATTR amyloidosis patient were karyotypically normal (by G-banding 
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 Normal (wild type), corrected, and non-targeted, heterozygous TTRL55P 
iPSCs were differentiated into HLCs. Conditioned supernatant from each line was 
harvested after culturing cells for 72 hours in hepatic specification media beginning 
on day 16 of the differentiation. We used liquid chromatography (LC)/mass 
spectrometry (MS) to show that TTR immunopurified from normal hepatic 
supernatants contained TTRWT, but not TTRL55P, while supernatants collected from 
patient iPSC-derived HLCs contained both TTRWT and TTRL55P (Figure 4.3B). 
Supernatant from corrected iPSC-derived HLCs revealed complete elimination of 
TTRL55P, while levels of TTRWT remained unperturbed (Figure 4.3B). Importantly, 
the two amino acid overhang on the N-terminal portion of TTR, resulting from the 
post-translational cleavage of the 2A peptide, were removed with the TTR signal 
peptide through normal protein processing in the ER. This is made evident by the 
identical molecular weights observed for endogenous and exogenous TTRWT, 
showing that TTRWT from our donor construct is indistinguishable from the 
endogenous protein.  
 Many studies have shown that decreasing circulating levels of destabilized 
TTR species, as in the case of liver transplantation and our novel gene editing 
strategy, results in decreased peripheral organ dysfunction (Ericzon et al. 1999; 
Herlenius et al. 2004; Hemming et al. 1998). Therefore, we sought to determine 
the efficacy of our iPSC-based gene correction methodology in decreasing toxicity 
in a cell-based model. To accomplish this, a neuronal cell line (SH-SY5Y) was 
dosed with conditioned supernatant generated from mutant TTRL55P, corrected, or  
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Figure 4.3 Gene-edited iPSC-derived HLCs no longer produce neurotoxic, 
destabilized TTR variants.  
(A) Experimental overview depicting interrogation of normal, TTRL55P, and 
corrected iPSC-derived HLC supernatants and determination of their requisite 
downstream effects on neuronal target cells. (B) LC/MS analyses of supernatant 
from normal, TTRL55P, and corrected iPSC-derived HLCs. Red trace: TTRWT, pink 
trace: destabilized TTRL55P variant. Bovine TTR (green) is present in media 
supplements. The molecular weight of each species is denoted in daltons. (C) SH-
SY5Y cells were dosed for 7 days with conditioned iPSC HLC-derived supernatant 
from normal, TTRL55P, or corrected conditions. Cell viability was determined via PI 
staining (n=3, unpaired t-test for significance comparing uncorrected and corrected 
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normal HLCs, and surveyed for toxicity. In these assays, SH-SY5Y cells dosed 
with mutant hepatic supernatant displayed an increase in PI+ cells compared to 
those dosed with normal supernatant (Figure 4.3C). Cells dosed with corrected 
supernatant, however, exhibited a modest, though not statistically significant 
(p=0.0525), decrease in toxicity comparable to levels observed in the normal 
control sample (Figure 4.3C). These results suggest that the proposed gene 
correction strategy ameliorates TTR-mediated toxicity via reductions in the hepatic 
secretion of destabilized TTR. 
 
4.4 Single cell RNA sequencing reveals a novel hepatic gene signature 
associated with the production of destabilized TTRL55P  
It has been thought that the livers of patients with ATTR amyloidosis are unaffected 
during disease pathogenesis (Ando et al. 2005; Benson 2012; Blancas-Mejia and 
Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 1997; Merlini and Westermark 
2004; Reixach et al. 2004; Ruberg and Berk 2012; Wechalekar et al. 2016). 
Several studies however, calling into question the use of donor organs from ATTR 
amyloidosis patients for DLT procedures, challenges this notion (Ericzon 2007; 
Llado et al. 2010; Misumi et al. 2016; Muchtar et al. 2017; Stangou et al. 2005; 
Yamamoto et al. 2007). Furthermore, evidence highlights a significant potential 
role for the liver in regulating the extracellular aggregation and distal deposition of 
TTR implicated in ATTR amyloidosis disease pathogenesis (Buxbaum et al. 2012). 
Collectively, these results indicate that genetic or aging-related perturbations to 
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the liver could influence the toxic extracellular aggregation and deposition of TTR 
aggregates on peripheral target tissues.  
 In order to define specific hepatic proteins and pathways associated with 
the production of destabilized, amyloidogenic TTR variants, we coupled our TTR 
reporter system with single cell RNA sequencing (scRNAseq) to compare mRNA 
expression profiles in syngeneic iPSC-derived HLCs with or without the TTRL55P 
mutation. In addition to our corrected TTR reporter iPSC line, we also constructed 
a reporter cell line where our TTR-GFP donor construct was targeted to the wild-
type TTR allele in the same TTRL55P parental iPSC line. As a result, we created 
two syngeneic, TTR-promoter driven hepatic-specification reporter iPSC lines, 
where the only difference is the presence or absence of the disease causing 
TTRL55P mutation (henceforth referred to as uncorrected and corrected cells, 
respectively). To compare HLCs +/- TTRL55P, uncorrected and corrected reporter 
iPSCs were subjected to our hepatic specification protocol until TTR expression 
had plateaued (at day 16 of the differentiation) (Figure 4.1D). To control for the 
inherent heterogeneity of iPSC differentiations, GFP+ cells were purified by FACS 
to select for cells undergoing hepatic-specification (i.e. at similar stages in their 
developmental trajectories). Employing scRNAseq in combination with our FACS-
based purification strategy, we significantly reduce the potential for differences in 
corrected and uncorrected cells resulting from maturational status. Transcriptomic 
profiling was subsequently performed at single cell resolution via the Fluidigm C1 
platform (Figure 4.4A).  
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 Day 16 uncorrected and corrected HLCs formed clear and distinct groups 
by supervised principal component analysis (PCA), with 92 genes differentially 
expressed between the two groups (Figure 4.4B-D, Table 4.1) (significance 
determined via one-way ANOVA, FDR cutoff<0.05). These analyses identified 
increased expression of distinct genes and pathways previously shown to 
influence extracellular aggregation of destabilized TTRs in uncorrected but not 
corrected HLCs (vide infra) (Chen et al. 2014; Chen et al. 2016; Genereux et al. 
2015; Plate et al. 2016; Shoulders et al. 2013).   
 
4.5 Transferrin expression is significantly increased in uncorrected HLCs 
and inhibits aggregation of destabilized TTR 
The top differentially expressed gene in uncorrected HLCs is the iron transporter, 
transferrin (TF) (Figure 4.4C, D). Although TF is a known hepatic lineage marker 
(Figure 4.1A), no other hepatic markers (including: TTR, ALB, AFP, HNF4A, 
FOXA1, GATA4, SERPINA1, FGB, DUOX2, A2M, TGM2, HAVCR1, GATA6) are 
differentially expressed between corrected and uncorrected HLCs, suggesting that 
the differential expression of TF is not simply due to the differentiation status of 
individual lines (Figures 4.4D, 4.5). Interestingly, previous studies have 
demonstrated the ability of TF to act as a chaperone in the context of other amyloid 
disorders such as Alzheimer’s Disease (AD) as well as to physically interact with 
TTR fibrils in vivo (Ohta et al. 2018). As a result, we sought to assess the capacity  
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Figure 4.4 Single cell RNA sequencing (scRNAseq) of corrected vs. 
uncorrected syngeneic iPSC-derived HLCs reveals a novel hepatic gene 
signature.   
(A) Experimental schematic for the transcriptomic comparison of uncorrected 
(TTRL55P-expressing) and corrected syngeneic iPSC-derived HLCs at day 16 of 
the hepatic specification protocol. (B) Uncorrected (red) and corrected (green) 
populations form distinct groups by supervised principal component analysis 
(PCA). Supervised PCA was constructed using the top 500 differentially expressed 
genes by FDR.  (C) Heatmap depicting the 92 genes differentially expressed 
between uncorrected and corrected populations (one-way ANOVA, FDR 
cutoff<0.05). Columns represent individual cells, green bar denotes corrected 
cells, red bar denotes uncorrected cells. Rows represent differentially expressed 
genes. The top 10 genes by foldchange (uncorrected over corrected) as well as 
proteostasis factor EDEM2 are highlighted on the y-axis. (D) Violin plots 
representing relative expression levels of TTR, potential mediators of TTR 
fibrillogenesis (TF), and UPR target genes (HYOU1, EDEM2). (FDR determined 
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Table 4.1 Differentially expressed genes correlating with expression of destabilized, disease-causing 
TTRL55P. 
The above table depicts a list of genes which are differentially expressed in uncorrected, TTRL55P-expressing iPSC-
derived HLCs compared to their syngeneic, corrected counterparts. Fold-change depicted represents the 
expression of uncorrected over corrected cells. Statistics calculated comparing uncorrected to corrected HLCs. 
logFC: log of fold-change; FDR: false discovery rate.
Gene ID logFC Avg. Expression t-value Variance p-value FDR
TF 4.081821634 7.378995719 6.470503141 15.32077033 2.07E-09 2.50E-05
PIGT 2.283104606 4.930281711 4.856672602 7.493945492 3.54E-06 0.006129132
RASSF7 2.108881836 4.021970246 4.651879495 6.86499951 8.33E-06 0.00746791
ADAMTS12 2.096247897 2.772907621 4.566823897 7.002841594 1.18E-05 0.008948328
HYOU1 2.064948028 4.571160548 4.311317903 7.515176191 3.28E-05 0.015929769
BEX1 2.027022298 4.805756188 4.179528656 7.647370028 5.48E-05 0.022928326
GMPS 1.963038036 2.48804106 5.246575073 4.823620587 6.52E-07 0.002611484
TMEM258 1.945818833 6.540858568 5.256859336 4.721226902 6.23E-07 0.002611484
POLR3A 1.932548533 3.346158807 4.217828736 6.825729229 4.73E-05 0.021241179
RPRD1B 1.913247435 2.503005719 5.091060889 4.814161089 1.29E-06 0.002611484
METTL23 1.849125602 2.811636979 4.198732354 6.287742941 5.09E-05 0.022052445
CCDC47 1.835734493 4.503869028 4.606869978 5.255390879 1.00E-05 0.008103296
ADM 1.818411964 3.934329415 3.676138949 7.733641888 0.000351633 0.047376638
CPNE1 1.801377287 5.769281516 4.745555899 4.799536961 5.65E-06 0.007218041
ALG3 1.787356286 3.162952302 3.958923664 6.521630445 0.000126285 0.030626602
MT-ATP8 1.7834897 7.247317613 5.156830666 4.073994484 9.69E-07 0.002611484
OSER1 1.745007235 3.526000844 3.928758099 6.296375601 0.000141209 0.031668146
DEF8 1.719501334 3.843121702 4.047892924 5.786993914 9.05E-05 0.02744603
MPZL2 1.713511719 2.134677623 4.374249084 4.998617643 2.56E-05 0.014119919
SEPHS2 1.70977782 3.4943106 3.81648574 6.367089039 0.000212905 0.04033876
NDUFS1 1.700457442 4.435529224 4.699641286 4.334182076 6.84E-06 0.007218041
KMT5B 1.693491989 2.954675168 3.749790937 6.448718867 0.000270668 0.042025018
SPATA20 1.693257922 4.141270319 3.746584411 6.457030994 0.00027379 0.042025018
COL4A2 1.689854095 5.353125423 4.008390564 5.684383451 0.000105017 0.027881048
FIS1 1.680691839 4.782510367 3.974037991 5.709939317 0.000119385 0.029544225
CREB3 1.667405803 3.127040014 3.716494221 6.350433685 0.000304796 0.044529658
CSNK2A1 1.655018681 3.664743861 4.400428639 4.604135892 2.31E-05 0.013330691
NGLY1 1.649685313 2.591742706 3.942086342 5.577298309 0.000134418 0.031409186
CINP 1.640065524 4.020242315 4.000740878 5.364524598 0.000108066 0.027881048
SRA1 1.637618912 4.093278454 3.748725692 6.023936925 0.000271701 0.042025018
TEX10 1.632363396 3.069479647 4.099978855 5.081818136 7.43E-05 0.026512402
PBRM1 1.629930864 4.191621877 3.805714694 5.803046807 0.000221364 0.040670584
TTI2 1.612303702 2.196776013 3.739299056 5.861782539 0.00028101 0.042594116
TTI1 1.580007393 2.070942465 4.020146378 4.924787386 0.000100491 0.027881048
ERLIN1 1.563825255 2.941907782 3.841319683 5.239908292 0.000194556 0.03805142
GTPBP4 1.560781288 3.398793399 3.892197387 5.094511553 0.000161554 0.034368491
ARMCX1 1.558065092 1.83899433 4.057109525 4.705868028 8.74E-05 0.027205804
MRPL17 1.554729441 4.119808388 4.689054338 3.613674947 7.14E-06 0.007218041
RNF4 1.554552465 2.282664675 3.936388179 4.949400015 0.000137282 0.031409186
PRNP 1.553224051 3.834024467 3.758680359 5.378105623 0.000262189 0.042025018
NME1 1.547738166 4.707662064 3.705185497 5.482293839 0.000317288 0.044737598
APOA2 1.541646894 7.237015807 4.352637033 4.054401364 2.79E-05 0.014709594
RNASEH2C 1.523769091 1.936155404 3.806509314 5.051483572 0.000220729 0.040670584
ELOC 1.517575948 4.916247193 4.29401237 4.021279192 3.51E-05 0.016393336
ADK 1.516832106 2.939697847 3.818143106 4.976231939 0.00021163 0.04033876
MT-ND4L 1.511178361 6.548005332 3.900153049 4.748925272 0.000156902 0.033974943
Gene ID logFC Avg. Expression t-value Variance p-value FDR
ZNF28 1.504996165 2.532076261 3.756234882 5.04649045 0.000264496 0.042025018
SMIM11A 1.499465553 1.884699392 4.018761204 4.423851081 0.000101015 0.027881048
KIAA0319L 1.492406995 4.334954905 4.341918676 3.807282009 2.91E-05 0.014709594
PNO1 1.481272904 1.899435481 4.107367316 4.145356763 7.23E-05 0.026512402
NDUFAF3 1.479022443 3.021491176 3.792141775 4.784020684 0.000232479 0.041456479
MRPL41 1.473487546 6.40349842 4.485791218 3.496722499 1.64E-05 0.010466178
GOT2 1.46697696 4.563674641 3.756613883 4.786603806 0.000264137 0.042025018
PTDSS1 1.464975031 2.366801806 3.709322594 4.886421271 0.000312663 0.044604122
EDEM2 1.447330135 1.695523435 5.100653354 2.684011707 1.24E-06 0.002611484
LINC00665 1.446933854 1.074613843 4.797303648 2.987187207 4.55E-06 0.006890109
OST4 1.444748976 4.091516247 4.643522764 3.154979658 8.62E-06 0.00746791
RABAC1 1.440534895 5.710213206 3.767155127 4.586562861 0.000254341 0.042025018
CHCHD2 1.422066175 4.747126021 3.924138688 4.141712195 0.000143637 0.031668146
STMP1 1.411507888 4.512694845 4.106452375 3.752245242 7.25E-05 0.026512402
FCF1 1.407580383 2.436977621 4.06370704 3.802705805 8.53E-05 0.027205804
DARS2 1.383814426 1.407260695 4.001860399 3.775349895 0.000107615 0.027881048
PHF23 1.367003151 2.301118626 3.848078617 3.956769484 0.000189829 0.037735503
PPRC1 1.364881881 1.496702838 3.851476649 3.937608331 0.000187494 0.037735503
LARP7 1.356326607 4.16728555 3.870905377 3.85054285 0.000174659 0.036515674
TAF10 1.349785173 4.896739444 4.056937356 3.495852956 8.75E-05 0.027205804
TM9SF2 1.346608447 5.372013185 3.981078076 3.601763993 0.000116296 0.029379248
DYNLRB1 1.344193629 5.39391816 3.684869967 4.141697404 0.000340956 0.046454244
1.326309843 1.406295461 3.93824766 3.560103335 0.000136341 0.031409186
CDK10 1.317660825 0.996429158 4.529328834 2.719238785 1.38E-05 0.009567765
ZFP82 1.315762474 1.058143875 4.125009737 3.2146801 6.76E-05 0.026512402
PPDPF 1.288981762 5.490187493 4.001883551 3.256373053 0.000107605 0.027881048
PSMB5 1.279087735 5.748781065 4.074754071 3.099249229 8.18E-05 0.027205804
ZNF700 1.261225716 1.308839575 3.78024802 3.459408046 0.000242653 0.042025018
MT-CO2 1.256938333 9.918817699 4.123073334 2.923502497 6.81E-05 0.026512402
CALML4 1.237863863 1.311387297 3.686226337 3.487893623 0.000339325 0.046454244
NDUFB8 1.227737789 5.616309968 4.022820018 2.912447169 9.95E-05 0.027881048
TMEM237 1.214313512 1.673843497 3.718519934 3.296498977 0.000302609 0.044529658
MT-ND1 1.213039348 7.532575485 3.799242478 3.159422845 0.0002266 0.041011148
ZSWIM1 1.162413503 1.281554874 3.733682082 2.985596408 0.0002867 0.042920029
LINC01764 1.134711122 0.74070213 3.695335815 2.894073543 0.000328562 0.045794679
RPL7A -0.617436959 6.742355673 -3.856731173 0.688256623 0.000183937 0.037735503
RPL24 -0.669594458 7.293513925 -4.704319607 0.548160911 6.70E-06 0.007218041
SLITRK4 -0.845495187 1.712353513 -3.654936895 1.575973126 0.000378893 0.049939742
AC009501.1 -0.906029383 3.110809047 -3.762188578 1.731017446 0.000258913 0.042025018
AL024508.2 -0.959264324 1.8578006 -3.759558362 1.960619217 0.000261366 0.042025018
ANKRD45 -0.960127216 0.523003056 -3.672786889 2.054912361 0.000355815 0.047413367
CXCL11 -1.186551538 0.711093531 -3.747089981 3.096032231 0.000273295 0.042025018
NOS3 -1.242501212 0.73307302 -4.091116722 2.894751721 7.69E-05 0.026636548
CEP85L -1.436948794 1.530429627 -3.712421657 4.688473874 0.00030924 0.044604122
UGT2B7 -1.540196826 0.803336773 -4.521377361 3.780302281 1.42E-05 0.009567765
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for TF to act as a chaperone for misfolding TTR and in turn prevent TTR fibril 
formation. To this end, we performed an in vitro fibril formation assay whereby the 
formation of congophilic fibrils from bacterial-derived, recombinant TTRL55P was 
assessed with or without the addition of TF (Figure 4.6A) (Klunk et al. 1989). In 
doing so, iron-free TF (apo-transferrin) at physiologically-relevant concentrations 
(30 µM) reduced the amount of congophilic species formed by approximately 60% 
(Figure 4.6B). Notably, iron-bound holo-transferrin, at similar concentrations, was 
found to have no effect on fibril formation (data not shown) perhaps owing to well-
documented iron binding-induced conformational changes (Yang et al. 2012). This 
suggests that the increased expression of TF in HLCs containing mutant TTRL55P 
could represent a mechanism to suppress aggregation-associated toxicity.   
 
4.6 Uncorrected HLCs show increased activation of protective UPR-
associated signaling pathways  
Apart from TF, our scRNAseq analysis also identified increased expression of 
multiple UPR-regulated ER proteostasis factors (e.g., HYOU1 and EDEM2; Figure 
4.4C, D) in iPSC-derived HLCs expressing TTRL55P. These genes play important 
roles in regulating proteostasis within the ER. Thus, the increased expression of 
these ER proteostasis factors suggests that the presence of the destabilized 
TTRL55P protein challenges the ER proteostasis environment and in turn activates 
UPR-associated signaling pathways.  
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Figure 4.5 Liver markers are not differentially expressed between 
uncorrected and corrected HLCs at day 16 of differentiation.  
Violin plots representing equivalent relative expression levels of genes known to 
be upregulated during hepatic specification of PSCs in uncorrected (red) and 
corrected (green) HLCs. None of the noted genes are differentially expressed 
between the two groups, suggesting competent normalization of the hepatic 
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Figure 4.6 Assessment of TF chaperone capacity and functional validation 
of XBP1 activation in ATTR amyloidosis hepatic cells.  
(A) Experimental outline for assessing TF’s in vitro ability to prevent the formation 
of congophilic species from recombinant TTRL55P. (B) Percentage of TTRL55P fibrils 
formed as determined by amount of Congo red (CR) bound after 24-hour 
incubation of recombinant protein under fibril forming conditions (n=5, *p<0.05, one 
sample t-test for significance comparing apo-TF condition to TTRL55P alone). (C) 
GSEA depicting significant enrichment of adaptive UPR machinery (ATF6, XBP1s) 
but not PERK target genes in uncorrected HLCs. In these analyses, 100 
uncorrected and 60 corrected cells were studied. (D) Depiction of XBP1 splicing in 
the presence of ER stress and UPR activation. (E) PstI analytical digest of 
amplified XBP1 transcripts from iPSCs treated with thapsigargin (Tg), wild-type 
iPSC-derived HLCs (WT), and ATTR HLCs differentiated from two patient-specific 
iPSC lines (L58H and I107M). Hybrid band represents a PstI-resistant spliced-
unspliced XBP1 product generated via PCR protocol. (F) Densitometric 
quantitation of PstI-digested XBP1 transcripts. Ratio determined by 


 .  
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 Interestingly, ER stress and UPR activation can influence the toxic 
extracellular aggregation of amyloidogenic TTR mutants implicated in ATTR 
amyloidosis disease pathogenesis (Chen et al. 2014; Chen et al. 2016; Genereux 
et al. 2015; Plate et al. 2016; Shoulders et al. 2013). Chemical toxins that induce 
severe, unresolvable ER stress in mammalian cells decrease the population of 
amyloidogenic TTR secreted as the native TTR tetramer and instead increase TTR 
secretion in non-native conformations that rapidly aggregate into soluble oligomers 
implicated in ATTR amyloidosis disease pathogenesis (Chen et al. 2016, Romine 
and Wiseman 2018). In contrast, enhancing ER proteostasis through the stress-
independent activation of the adaptive UPR-associated transcription factor ATF6, 
selectively reduces the secretion and subsequent aggregation of destabilized, 
amyloidogenic TTR variants (Chen et al. 2014; Genereux et al. 2015; Plate et al. 
2016; Shoulders et al. 2013). This suggests that activation of adaptive UPR 
signaling pathways independent of severe ER stress is a protective mechanism to 
suppress the secretion and toxic aggregation of destabilized, amyloidogenic TTR 
mutants.  
In order to better define the effect of TTRL55P expression on ER stress and 
UPR activation, we used gene set enrichment analysis (GSEA) to define the extent 
of UPR pathway activation in our uncorrected iPSC-derived hepatic lineages. 
Notably, this analysis revealed modest activation of the adaptive IRE1/XBP1s and 
ATF6 UPR transcriptional signaling pathways, with no significant activation of the 
pro-apoptotic PERK UPR pathway (Figure 4.6C). We confirmed IRE1/XBP1s 
 
   82
activation in two independent patient-specific iPSC-derived HLCs by monitoring 
IRE1-dependent XBP1 splicing (Figure 4.6D-F). As a positive control, cells were 
dosed with global UPR activator thapsigargin. These results show that expression 
of destabilized, amyloidogenic TTRL55P promotes remodeling of ER proteostasis 
through the IRE1/XBP1s and ATF6 UPR signaling pathways.    
 
4.7 Hepatic activation of ATF6 signaling selectively reduces secretion of 
destabilized TTRL55P 
We next determined the consequence of functional activation of adaptive UPR-
associated signaling pathways in ATTR amyloidosis patient-specific iPSC-derived 
hepatic cells expressing mutant, destabilized TTR. To accomplish this, we 
introduced an ATF6-inducible donor construct into our previously described 
heterozygous TTRL55P patient-specific iPSC line. In these cells, the coding 
sequence for the active N-terminal bZIP transcription factor domain of ATF6 is 
fused to a destabilized dihydrofolate reductase (DHFR) tag as previously 
described (Shoulders et al. 2013). In the absence of chemical chaperone 
trimethoprim (TMP), the DHFR.ATF6 protein product is targeted for degradation 
via the ubiquitin proteasome system (Figure 4.7A). Upon administration of TMP, 
the DHFR domain is stabilized, allowing dosable, stress-independent activation of 
ATF6 transcriptional activity (Figure 4.7A). ATF6-inducible iPSCs were 
differentiated into HLCs and subsequently dosed with TMP, beginning on day 15 
of hepatic specification (Figure 4.7B). Administration of TMP induced selective 
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expression of the ATF6 target genes HSPA5 and HERPUD1, but not an 
IRE1/XBP1s target gene (e.g. ERDJ4) or PERK target gene (e.g. GADD34) 
(Figure 4.7C, E), confirming selective TMP-dependent ATF6 activation in these 
HLCs. We then collected conditioned media for 72 hours on patient iPSC-derived 
HLCs dosed with or without TMP and monitored the relative populations of TTRWT 
and TTRL55P by mass spectrometry. We initially showed that the relative recovery 
of TTRL55P from IPs of media prepared on HLCs treated with TMP was reduced 
relative to TTRWT, suggesting reduced secretion of this destabilized TTR variant 
induced by stress-independent ATF6 activation (Figure 4.8A, B). In order to 
ensure that observed decreases in hepatic secretion of TTRL55P is not due to 
differences in our ability to pull-down different TTR species (e.g., wild-type versus 
mutant as well as various conformational states), we employed an unbiased MS 
approach not relying on IP. In line with this, we performed Tandem Mass Tag 
(TMT) / LC-MS/MS quantitative proteomics to directly monitor the relative amounts 
of peptides comprising TTRWT or TTRL55P in these conditioned media (Figure 
4.7D). Using this quantitative approach, we show that TMP-dependent ATF6 
activation preferentially reduces levels of destabilized TTRL55P 25% relative to 
TTRWT in HLC conditioned media. This demonstrates that stress-independent 
ATF6 activation selectively reduces secretion of destabilized, amyloidogenic 
TTRL55P in patient iPSC-derived HLCs. We moreover found that branch-specific 
activation of ATF6 signaling protects iPSC-derived HLCs from morphological  
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Figure 4.7 Hepatic stress-independent, branch-specific activation of 
adaptive UPR-associated ATF6 signaling results in the targeting and 
selective reduction in the secretion of destabilized TTRL55P.  
(A) A chemical inducible system for activating ATF6 signaling in TTRL55P iPSC-
derived cell types. In the absence of chemical chaperone TMP, DHFR.ATF6 is 
degraded. Upon addition of TMP, DHFR.ATF6 is stabilized and targets and 
attenuates the secretion of misfolded TTRs. (B) ATF6-inducible iPSCs were 
differentiated into HLCs. TMP was added and conditioned supernatant was 
collected and interrogating for the presence and relative abundance of different 
TTR species via LC/MS-MS. (C) ATF6 target gene HSPA5 was found to be 
significantly upregulated upon addition of TMP by qRT-PCR (n=4, *p<0.05, 
unpaired t-test for significance comparing -TMP to +TMP conditions). (D) LC-
MS/MS was used to directly detect the presence of TTRWT (upper peptide 
sequence, black) and TTRL55P (lower peptide sequence, orange) peptides in 
conditioned supernatant in the presence and absence of TMP. Abundance of 
TTRL55P was found to significantly decrease upon activation of ATF6 signaling by 
~25% relative to TTRWT. Quantities of each peptide were normalized to TTRWT 
(n=3, **p<0.05, unpaired t-test for significance comparing normalized quantities of 
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TTRWT and TTRL55P). (E) Upon addition of TMP, ATF6 target gene HERPUD1 was 
found to be significantly upregulated compared to DHFR.ATF6 HLCs in the 
absence of TMP. IRE1/XBP1s and PERK target genes ERDJ4 and GADD34 
however, were not found to be differentially expressed in the presence of TMP. 
Positive control thapsigargin (Tg) was found to significantly upregulate expression 
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Figure 4.8 Activation of ATF6 signaling in ATTR amyloidosis patient-specific 
iPSC-derived HLCs results in selective decrease in the secretion of 
destabilized TTR.  
(A) Representative IP-MS data of the relative abundances of TTRL55P and TTRWT 
in non-targeted, heterozygous TTRL55P patient-specific HLCs. (B) Recovery of 
TTRL55P in conditioned ATF6-inducible HLC supernatant in the presence and 
absence of exogenous ATF6 activation (i.e. TMP) (n=4, unpaired t-test for 
significance). TTRL55P signal denoted is normalized to TTRWT in each replicate. (C) 
Individual experiments compiled/summarized in Figure 4.7. Error bars represent 
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defects resulting from prolonged exposure to severe ER stress via addition of 
thapsigargin (Figure 4.9).  
 
4.8 Summary and conclusions 
Herein, we describe the utilization of gene editing technology in ATTR amyloidosis 
patient-specific iPSCs in order to uncover a novel human hepatic gene signature 
resulting from the expression of destabilized, misfolding-prone TTR. Historically, 
the livers of patients with ATTR amyloidosis were thought to be unaffected in 
disease pathogenesis (Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 
2004; Falk et al. 1997; Merlini and Westermark 2004; Reixach et al. 2004; 
Wechalekar et al. 2016). This is best highlighted through the employment of DLTs, 
wherein the livers of patients with ATTR amyloidosis are removed and given to 
individuals in end-stage liver failure. Despite routine use of these transplants, 
recent clinical data demonstrates that non-ATTR amyloidosis DLT recipients not 
only go on to develop amyloidogenic TTR fibrils (and disease), but they do so at a 
median time of only 7.5 years post-transplant (Ericzon et al. 2007; Llado et al. 
2010; Misumi et al. 2016; Muchtar et al. 2017; Stangou et al. 2005; Yamamoto et 
al. 2007). While these clinical observations suggest a role for the liver in 
contributing to pathogenesis of ATTR amyloidosis and potentially other systemic 
amyloid diseases, the cellular and molecular mechanisms for this phenomenon 
remain unknown. 
 












Figure 4.9 Branch-specific activation of ATF6 signaling in patient-specific 
iPSC-derived hepatic cells alleviates ER stress-mediated morphological 
defects. 
(A) Inducible ATF6 iPSCs were differentiated into HLCs and exposed to global ER 
stress via addition of thapsigargin. In addition to the presence of thapsigargin, 
ATF6 signaling was either activated via addition of TMP or inhibited via addition of 
small molecule CP7. After 5 days of exposure to each compound, cells were 
observed for morphological defects. (B) In the absence of TMP, in the presence of 
thapsigargin, cells exhibited gross morphological defects. Upon activating ATF6 
signaling (in the presence of thapsgargin), morphology appeared to be rescued. 
Conversely, upon inhibiting ATF6 signaling via addition of CP7 (in the presence of 
thapsigargin), morphological defects were noted. Cells were dosed with various 
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 Through the use of gene editing and scRNAseq, we defined distinct 
transcriptional profiles for hepatic cells expressing destabilized TTRL55P. We 
hypothesized that hepatic production of destabilized TTRs results in the 
upregulation of stress-responsive proteostasis factors that regulate the secretion 
and subsequent aggregation of destabilized TTR variants such as TTRL55P. Our 
scRNAseq experiment revealed that uncorrected hepatic cells exhibited differential 
expression of 92 genes compared to syngeneic hepatic cells where the only 
difference is the absence of expression of the mutant TTR. In line with our 
rationale, we identified many instances in which mutant hepatic cells upregulated 
expression of well-documented ER stress-associated proteostasis factors involved 
in regulating protein secretion (e.g. HYOU1, EDEM2).  
 Interestingly, TF was found to be the most upregulated gene in uncorrected, 
TTRL55P-expressing hepatic cells. Despite limited prior evidence for TF as a 
chaperone for misfolded TTRs, recent work implicates its chaperone capacity in 
other amyloid disorders such as Alzheimer’s Disease (AD), noting increased 
protein-level expression in the prefrontal cortices of AD patients compared to 
elderly, non-diseased individuals (Loeffler et al. 1995). Moreover, recent work 
demonstrated the ability of TF to physically interact with and prevent the self-
assembly and toxicity of amyloid β peptide (Aβ) oligomers, the amyloidogenic 
protein species in AD (Giunta et al. 2004; Raditsis et al. 2013). At the same time, 
recent in vivo data have demonstrated physical interactions between TF and TTR 
amyloid fibrils (Ohta et al. 2018). Through the use of congophilic fibril formation 
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assays, we demonstrated that iron-free TF at physiologically relevant levels, 
decreased in vitro TTRL55P fibril formation by approximately 60%, implicating TF as 
a novel chaperone for hepatic TTRs. These observations, together with our 
scRNAseq and biochemical data, suggest the possibility that TF plays a similar 
protective role in ATTR amyloidosis. In this model, hepatic cells producing mutant 
TTR may express higher levels of TF to prevent toxicity and/or fibril formation. 
In addition to the differential expression of known and novel chaperone 
genes, we noted activation of the adaptive arms of the UPR (ATF6 and 
IRE1/XBP1s) in hepatic cells expressing mutant TTR. Together, these data 
indicate that the expression of TTRL55P in iPSC-derived HLCs does not induce 
severe ER stress, but suggests that the activation of adaptive IRE1/XBP1s and 
ATF6 signaling observed in these cells reflects a protective mechanism to 
suppress secretion and subsequent aggregation of the destabilized TTRL55P 
protein. Consistent with this, our IP-based LC-MS analysis of conditioned media 
from uncorrected HLCs showed that TTRL55P levels were approximately 30% that 
of TTRWT (Figure 4.3B). This result mirrors the lower levels of destabilized TTR 
mutants (as compared to wild-type TTR) observed in conditioned media prepared 
on hepatic cells expressing both variants (Chen et al. 2014; Chen et al. 2016; 
Genereux et al. 2015; Giadone et al. 2018; Leung et al. 2013; Leung and Murphy 
2016; Plate et al. 2013; Shoulders et al. 2013).  
 Our scRNAseq experiments demonstrate activation of proteostasis 
transcriptional networks consisting of upregulation of chaperones as well as 
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functional activation of adaptive UPR-associated signaling pathways in mutant 
HLCs. Due to the gradual nature of the deposition of TTR aggregates and fibrils, 
with disease manifesting clinically around the 5th or 6th decade of life, ATTR 
amyloidosis is widely considered an aging-related disorder. It is well-understood 
that proteostasis factors and the ability to cope with the production of misfolded 
proteins decreases with age, while similarly, iron has been shown to increase in a 
number of organs throughout aging (Bloomer et al. 2008; Cook et al. 1998; Giunta 
et al. 2004; Jung et al. 2008; Loeffler et al. 1995; Raditsis et al. 2014). Interestingly, 
since UPR signaling declines during normal aging (Hipp et al. 2019; Kaushik et al. 
2015; Klaips et a. 2018; Labbadia and Morimoto 2015), the presence of adaptive 
UPR signaling in the above-mentioned HLCs could reflect protective biologic 
pathways whose activity also decline during the aging process. Aging-dependent 
reductions in adaptive UPR signaling could exacerbate TTRL55P-associated ER 
stress and increase secretion of TTR in non-native conformations that facilitate 
toxic extracellular aggregation. Thus, monitoring changes in hepatic UPR 
activation and/or conformational stability of circulating TTR tetramers could reflect 
a potential biomarker to monitor progression of TTR amyloid disease pathogenesis 
(Schonhoft et al. 2017) – a notoriously difficult disorder to diagnose. 
Together, these results indicate that the expression of a destabilized, 
aggregation-prone protein upregulates proteostasis factors as well as functionally 
activates adaptive UPR-associated signaling pathways in ATTR amyloidosis 
patient-specific iPSC-derived hepatic cells. Moreover, we demonstrated that 
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inducible activation of ATF6 signaling in these cells resulted in a ~25% reduction 
of destabilized TTRL55P while wild-type levels appeared unaffected. Although a 
relatively modest decrease, this reduction could represent a shift toward stability 
where properly folded, mutant TTRs form stabilized heterotetramers with wild-type 
TTRs (Rappley et al. 2014). 
Conventional therapeutics for many systemic amyloid diseases involve 
decreasing circulating levels of the amyloidogenic protein. In the case of ATTR 
amyloidosis, for example, liver transplantation relies upon eliminating circulating 
levels of mutant TTR. Similarly, emerging RNAi-based therapeutics are being 
developed to target and eliminate wild-type and mutant TTR transcripts within liver 
tissue (Adams et al. 2018; Benson et al. 2018; Butler et al. 2016; Buxbaum 2018). 
Activating ATF6 signaling in ATTR amyloidosis hepatic cells could result in a 
therapeutic decrease in the secretion of misfolding-prone TTRs from the liver and 
thus a decrease in extracellular deposition of proteotoxic aggregates as distal 
target tissues. Recent studies have demonstrated that stress-independent, 
selective activation of ATF6 signaling is achievable via addition of small molecules 
(Chen et al. 2014; Glembotski et al. 2019; Shoulders et al. 2013). At the same 
time, upregulation of ATF6 signaling is relatively tolerated in humans with 
hyperactivating mutations (Glembotski et al. 2019; Hemming et al. 1998; Ohta et 
al. 2018). Future work will aim to further the development of small molecule-based 
ATF6-modulating compounds for the treatment of systemic amyloid diseases such 
as ATTR amyloidosis.   
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Results from these experiments challenge the long-held notion that the 
livers of patients with ATTR amyloidosis are unaffected by the disease and do not 
contribute to pathogenesis. Through the use of our novel iPSC-based model, our 
work demonstrates that expression of amyloidogenic TTR results in transcriptional 
and functional changes in ATTR amyloidosis hepatic cells. Moreover, these data 
suggest that the liver employs adaptive UPR-associated signaling pathways in 
order to cope with the production of misfolding-prone TTRs by selectively 
decreasing their secretion. Furthermore, this work demonstrates that modulation 
of UPR-associated ATF6 signaling results in a selective decrease in the secretion 
of misfolded proteins in patient-specific iPSC-derived hepatic cells, and could 
potentially represent a broadly applicable therapeutic strategy for complex and 
diverse systemic amyloid disorders. 
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CHAPTER FIVE. DEFINING MOLECULAR SIGNATURES OF HEREDITARY 
ATTR AMYLOIDOSIS. 
5.1 Introduction 
Transthyretin amyloidosis (ATTR amyloidosis) is a multi-system, autosomal 
dominant protein folding disorder with complex pathology and genetics. In ATTR 
amyloidosis, the liver secretes transthyretin (TTR) which misfolds due to the 
presence of a destabilizing mutation, decreases or defects in protein homeostasis 
machinery, or other mechanisms (Adams et al. 2020; Ando et al. 2005; Benson 
2012; Gertz et al. 2015; Giadone et al. 2018; Leung et al. 2013; Leung and Murphy 
2016; Reixach et al. 2004; Ruberg and Berk 2012). Secreted, misfolded TTR 
subsequently travels throughout circulation where it aggregates and deposits 
extracellularly at downstream target organs, most commonly the heart and 
peripheral nerves (Adams et al. 2020; Ando et al. 2005; Benson 2012; Gertz et al. 
2015; Giadone et al. 2018; Leung et al. 2013; Leung and Murphy 2016; Reixach 
et al. 2004; Ruberg and Berk 2012). 
As stated previously, ATTR amyloidosis can result from the misfolding of 
wild-type or mutant TTR (Adams et al. 2020; Ando et al. 2005; Benson 2012; Gertz 
et al. 2015; Giadone et al. 2018; Leung et al. 2013; Leung and Murphy 2016; 
Reixach et al. 2004; Ruberg and Berk 2012).  Patients with the disease typically 
exhibit symptoms in the 5th or 6th decade of life (8th decade of life in the case of 
wild-type ATTR amyloidosis). A majority of patients with ATTR amyloidosis are 
heterozygous for the mutation. Depending on the inherited mutation, patients 
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exhibit large variations in severity (including ages-of-onset), responsiveness to 
therapeutics, and pathologies (e.g. target organs impacted) (Adams et al. 2020; 
Leung and Murphy 2016; Giadone et al. 2018).  
The gold standard diagnostic tool for patients with systemic amyloid 
disease, Congo red dye, is not always conclusive, and can lead to both false-
negatives and false-positives (Adams et al. 2020; El-Meanawy et al. 2019). 
Compounding this issue, the initial clinical presentation of both cardiomyopathy 
and peripheral neuropathy resulting from deposition of misfolded TTR aggregates 
is nonspecific, leading to many misdiagnoses (Marcus et al. 2012).  
As stated above, the disease is diagnosed by identification of TTR amyloid 
fibrils. Evidence however suggests that low molecular weight oligomers, the 
precursors to Congophilic TTR fibrils, are the major cytotoxic species which elicits 
damage at downstream cell types and organs (Reixach et al. 2004). It is therefore 
possible that cell and organ damage could take place prior to amyloid formation. 
As a result, novel biomarkers are needed to aid in the early diagnosis and 
treatment of this difficult to manage disease.  
Complicating the development of broadly efficacious therapeutics for the 
disorder, patients exhibit large variation in pathologies – largely dictated by the 
inherited mutation. Some mutations, such as the valine-to-methionine at position 
30 (TTRV30M) initially manifest in individuals with peripheral neuropathy (or TTR 
amyloid fibrils deposited throughout the peripheral nerves), whereas the valine-to-
isoleucine at position 122 (TTRV122I) are seen in patients with cardiomyopathy 
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(TTR fibrils throughout the cardiac tissue). The mechanisms for this phenomenon, 
termed organ tropism, are unknown (Maurer et al. 2017; Ton et al. 2015).  
Circulating aggregates of misfolded TTR deposit extracellularly at 
peripheral target tissues and elicit cell damage over the course of many years. 
Although well-documented, the mechanisms of cell death in ATTR amyloidosis are 
unclear. In peripheral neuropathy, Schwann cells are thought to be majorly 
damaged by proteotoxic TTR aggregates (Marukami et al. 2019). As Schwann 
cells, responsible for myelinating nearby neurons, begin to die, surrounding 
neurons lose stability. Resulting death in peripheral nerves can subsequently lead 
to clinical manifestation of symptoms including tingling/numbness in extremities.  
An in-depth understanding of the earliest insults of TTR-mediated 
stress/toxicity may lend insight into the development of novel biomarkers for 
patients with this notoriously difficult to diagnose disease. At the same time, 
assessing TTR-mediated signatures of damage at the cellular and molecular levels 
may provide mechanistic insight into how damage occurs and potentially lead to 
novel therapeutic targets.  
In this chapter, we employ bulk transcriptomics in order to profile changes 
resulting from exposure of pathologically diverse TTRs and overt stressors in cell 
types associated with the pathogenesis of ATTR amyloidosis. In doing so, we 
demonstrate each cell type responds to chemical- and TTR-mediated stress in 
distinct ways. Additionally, specific cell types exhibit unique responses at the 
transcriptional level when exposed to their respective clinically-associated TTR 
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variant (e.g. TTRV122I on cardiac cells). The signatures of TTR- and stress-
mediated cellular insult developed herein will allow for the further development of 
cell-based models for this and other systemic amyloid diseases. At the same time, 
identifying TTR variant- and cell-specific stress responses will provide a signature 
of mutation-specific organ tropism to enable studies into the mechanisms dictating 
this ill-defined phenomenon.  
 
5.2 Cells exposed to NaAsO2 exhibit increases in apoptosis and cell death 
as well as cell type-specific transcriptomic changes 
In order to establish a positive control for overt cellular toxicity applicable across 
diverse cell types, sodium (meta)arsenite (NaAsO2) (a known neurotoxic, 
cardiotoxic, and hepatoxic chemical) was exposed to neuronal SH-SY5Y, hepatic 
HepG2, and cardiac AC16 cells for 24 hours (Figure 5.1A) (Singh et al. 2011). A 
combinatorial annexin V-PI staining strategy was used in order to assess the 
percentages of viable, apoptotic, and necrotic cells by flow cytometry. Upon 
exposing cells to NaAsO2, hepatic HepG2 cells appeared to have minimal toxicity 
and morphological defects by microscopy and flow cytometry compared to naïve 
(non-dosed) conditions. Both neuronal and cardiac cell lines exhibited gross 
morphological changes and toxicity (Figure 5.1B). Annexin V-PI staining of 
exposed SH-SY5Y and AC16 cells demonstrated an overall decrease in the  
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Figure 5.1 Exposure to NaAsO2 elicits distinct transcriptomic responses in 
SH-SY5Y and AC16 cells. 
(A) Schematic overview of experiment. Briefly, cells were exposed to 10 µM 
NaAsO2 for 48 hours. Cells and RNA were harvested for flow cytometry-based cell 
death assay or transcriptomic profiling, respectively. (B) Brightfield images of naïve 
(untreated) and neuronal (SH-SY5Y), cardiac (AC16), and hepatic (HepG2) cells 
dosed with NaAsO2 for 48 hours. Cells were plated at equivalent densities 72 hours 
prior. (C) Annexin V-PI staining for naïve cells and those dosed with NaAsO2 for 
48 hours. Key (left) classifies viability status of each population. (D) Transcriptomic 
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profile of SH-SY5Y and AC16 cells exposed to NaAsO2 for 48 hours. Each circle 
denotes an individual gene. Red and blue circles denote significantly upregulated 
and significantly downregulated genes, respectively. Grey circles represent not 
significantly different expression. X-axis represents counts per million of gene, y-
axis represents log fold-change relative to naïve cells.    
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percentage of viable (double negative cells) when compared to their respective 
naïve conditions (94% vs. 86.9% and 87.7% and 53.4%, respectively) (Figure 
5.1C). In line with this observation, SH-SY5Y and AC16 cells were found to have 
increases in early and late apoptotic cell populations (Figure 5.1C). These shifts 
in viable and early/late apoptotic populations were not observed in HepG2 cells 
dosed with NaAsO2, consistent with morphology. A lack of damage observed in 
HepG2 cells could reflect differences in the cell type’s ability to respond to 
stressors, not enough resolution in the utilized annexin V-PI flow cytometry-based 
cell death assay, or activation of HepG2-specific stress pathways not detectible 
via these methodologies.  
 In addition to validating a flow cytometry-based method for assessing 
apoptosis/viability status, SH-SY5Y and AC16 cells -/+ NaAsO2 were subjected to 
bulk transcriptomic profiling. When compared to non-dosed controls, NaAsO2-
exposed SH-SY5Y cells exhibited significant differences in the expression of 5387 
genes (2841 upregulated, 2546 downregulated, FDR<0.05). Dosed AC16 cells 
were found to have significant differences in expression of 12068 genes (6079 
upregulated, 5989 downregulated). This greater number of genes differentially 
expressed by AC16 cells is potentially reflected by the larger difference in toxicity 
and apoptosis/cell death observed via annexin V-PI staining. 805 differentially 
expressed genes were found to be upregulated by both SH-SY5Y and AC16 cells, 
while 858 genes were found to be downregulated by both cell lines upon exposure 
to NaAsO2.  
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Interestingly, gene ontology (GO) analysis revealed that many genes 
upregulated in SH-SY5Y cells were associated with processes specific to the 
endoplasmic reticulum (ER), including many chaperones belonging to the heat 
shock family as well as genes associated with ER stress and apoptotic signaling 
cross-talk. AC16 cells on the other hand, exhibited differential expression of genes 
associated with regulation of translation, including many genes encoding 
ribosomal subunits (Figure 5.1E). Differences in genes differentially expressed by 
each cell type in response to NaAsO2 exposure could result from intrinsic 
differences in the available machinery within each cell type to respond to damage. 
Differentially expressed genes which are in common between cell types could 
reflect mechanisms utilized by both for oxidative stress recovery. 
 Gene sets from these experiments will serve as a positive control for 
assessing toxicity/stress resulting from exposure to pathologically-associated 
TTRs. Moreover, these data demonstrate cell type-specific transcriptional 
responses to overt cell toxicity.  
 
5.3 TTR exposure elicits cell type-specific transcriptional responses 
In order to assess early insults resulting from exposure to mutant TTRs, SH-SY5Y, 
AC16, and HepG2 cells were dosed with recombinant human TTR (rhTTR) 
variants clinically associated with cardiomyopathy or peripheral neuropathy 
(TTRWT, TTRV122I, and TTRL55P). Cells were dosed with 0.0125 mg/mL rhTTR for 
48 hours and harvested. In order to control for gene expression changes resulting 
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from the presence of misfolded protein, tafamidis was added in parallel conditions. 
RNA was isolated and bulk transcriptomic profiling was performed via the 
SmartSeq2 platform (Figure 5.2A). As a positive control for overt stress, SH-SY5Y 
and AC16 cells were exposed to NaAsO2 (described above). Cells were 
additionally exposed to a hyper-destabilized TTR variant associated with central 
nervous system involvement, TTRA25T. 
 As discussed above, NaAsO2 exposure resulted in extensive transcriptional 
changes in both SH-SY5Y and AC16 cells, clearly evident by PCA plots 
demonstrating clear separations between cells dosed with NaAsO2 and all TTRs 
(Figure 5.2B, top and middle plots). Transcriptomic differences between naïve 
and NaAsO2-exposed cells were greater than the differences between cells 
exposed to different TTRs. Moreover, PCA plots including all samples (-/+ each 
TTR and -/+ tafamidis) in each cell type suggest subtle transcriptional differences 
resulting from exposure to different TTRs (Figure 5.2B). Variations between 
technical replicates is equal to or greater than variations between biological 
replicates – likely due to the noise inherent to the SmartSeq2 platform.  
Neuronal SH-SY5Y and cardiac AC16 cells responded to the presence of 
NaAsO2 with distinct transcriptional signatures constituting varied biological 
processes (Figure 5.1D, E). This highlights the ability of cells to respond to stress 
in a cell type-specific manner. Despite noise in our dataset, we sought to 
understand how each cell type responded to the presence of TTR in general. To 
this end, the top 10 upregulated and downregulated genes in each condition  
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Figure 5.2 Cell exhibit type-specific transcriptomic responses upon 
exposure to pathologically-diverse TTRs.  
(A) Experimental overview. SH-SY5Y, HepG2, and AC16 cells were dosed with 
bacterial-derived recombinant human TTRs (rhTTRs) for 48 hours. Cells were 
harvested and stained with annexin V and PI and underwent bulk transcriptomic 
profiling. (B) Principle component analysis (PCA) plots of cells dosed with rhTTRs 
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represent exposure to different TTR species including plus tafamidis samples. (C) 
Heatmap depicting transcriptional signatures delineating AC16, HepG2, and SH-
SY5Y cells dosed with TTR in the absence of tafamidis. Columns denote individual 
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(including each cell type and TTR variant) were selected. The heatmap shown in 
Figure 5.2C depicts changes in expression of these genes across each cell type, 
forming clear transcriptional signatures delineating each. Similar to the 
aforementioned cell type-specific responses to NaAsO2, cells exhibit distinct 
transcriptional responses to the overall presence of TTR in the subset of genes 
assessed. Curiously, TTRWT appears to elicit changes in the expression pattern of 
assessed genes that is similar to when cells are exposed to mutant TTRs. Based 
off of the subset of genes analyzed, these data suggest that cells are capable of 
responding to TTRs (wild-type and mutant) in a cell type-specific manner.  
 
5.4 Cardiac AC16 and neuronal SH-SY5Y cells respond to pathologically-
associated TTRs with distinct transcriptional signatures  
We next wanted to assess if gene expression patterns change within the same cell 
type upon exposure to different TTRs. To do this, we further curated a list of genes 
from the abovementioned gene set (constituting the top up- and downregulated 
genes) and analyzed their expression across dosed cell types.  
 As expected, cardiac AC16 cells dosed with TTRWT did not exhibit a clear 
transcriptional signature by heatmap in the absence and presence of tafamidis 
(Figure 5.3A, left most heatmap). Similarly, dosing AC16 cells with peripheral 
neuropathy-associated TTRL55P did not evoke clear transcriptional differences -/+ 
tafamidis. Interestingly, exposing cardiomyopathy-associated TTRV122I on cardiac 
AC16 cells resulted in a transcriptional signature delineating the absence and  
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Figure 5.3 Target cell types respond to pathologically-associated TTR 
variants in a cell or variant-specific manner.  
Heatmaps depicting transcriptional response of cardiac AC16 and SH-SY5Y cells 
(A and B, respectively) to each TTR in the absence and presence of tafamidis. 
Fold-change depicted is row normalized and calculated relative to naïve (untreated 
cells). Left and right three columns represent technical triplicates. Moreover, left 
three columns represent the absence of tafamidis, right three columns depict the 
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presence of kinetic stabilizer tafamidis (i.e. the presence and absence of misfolded 
protein), suggesting changes in expression of these genes upon exposure to 
misfolded TTRV122I (Figure 5.3A). No difference in expression of genes was 
observed upon exposing cardiac AC16 cells to TTRA25T. 
Upon dosing neuronal SH-SY5Y cells with TTRWT, expression of a separate 
pre-determined gene set was not found to change -/+ tafamidis (Figure 5.3B, left 
most heatmap). Exposing SH-SY5Y cells to neuropathy-associated TTRL55P 
however, resulted in changes in expression of genes which attenuated upon 
addition of tafamidis (Figure 5.3B). This change in expression however was not 
observed when exposing SH-SY5Y cells to TTRV122I or TTRA25T. 
For all heatmaps shown, the left and right three columns represent technical 
replicates. This representation of these data underscores the noise associated with 
SmartSeq2 technology. As stated above, experiments will be performed to validate 
transcriptional signatures resulting from exposure to misfolded protein.   
 Together, these data begin to suggest that cells respond to destabilized 
TTR in both a variant- and cell type-specific manner. Alternatively stated, cardiac 
AC16 cells respond to cardiomyopathy-associated TTR differently than 
neuropathy-associated TTR. Conversely, neuronal SH-SY5Y cells respond to 
neuropathy-associated TTR differently than cardiomyopathy-associated TTR.  
 
5.5 Summary and conclusions 
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In patients with ATTR amyloidosis, liver-derived TTR subsequently deposits 
extracellularly at downstream target cell types which include Schwann cells of the 
peripheral nervous system and cardiomyocytes (Ando et al. 2005; Benson 2012; 
Gertz et al. 2015; Leung et al. 2013; Murakami et al. 2019; Reixach et al. 2004; 
Ruberg and Berk 2012). Although described clinically for many years, the 
mechanisms underlying TTR-mediated cell damage remain unclear. Here, we 
utilized transcriptomics to identify profiles of cell stress resulting from misfolded 
TTR exposure. 
In Figure 5.1, we demonstrate cell type-specific responses to global 
stressor NaAsO2. This observation, coupled with the goal of identifying TTR-
mediated stress signatures, led us to assess the potential for cell type-specific 
responses to destabilized TTR. Dosing neuronal SH-SY5Y, hepatic HepG2, and 
cardiac AC16 cells with rhTTRs we identified distinct transcriptomic profiles for 
each cell type, suggesting each cell responds to TTR via different mechanisms. 
Moreover, by dosing each cell type with pathologically-diverse TTR variants, we 
observed distinct transcriptional signatures unique to instances in which TTR 
variants were exposed to their disease-associated cell type. Furthermore, these 
signatures attenuated upon addition of kinetic stabilizer tafamidis, suggesting they 
resulted from the presence of the misfolded variant. It is worth noting that including 
other kinetic stabilizers such as diflunisal, a repurposed anti-inflammatory drug 
could result in alternative transcriptional profiles. 
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An example of transcriptional responses resulting from TTR exposure, can 
be seen in cardiac AC16 cells dosed with cardiomyopathy-associated TTRV122I. 
OMA1, for example, was found to be upregulated in cardiac AC16 cells upon 
exposure to TTRV122I alone. This difference in expression decreased upon addition 
of tafamidis. OMA1 has been implicated in mediating the mitochondrial UPR via 
alterations in mitochondrial polarization (Rainbolt et al. 2016). Future work will 
investigate changes in mitochondrial function (e.g. membrane polarization) as well 
as morphology within cardiac cells upon TTR exposure.   
 The immortalized cell lines used for the dosing experiments within this 
chapter were selected to due to their homogeneity relative to cell types 
differentiated from iPSCs. The SH-SY5Y cell line was subcloned from SK-N-SH 
cells which was isolated from neuroblastoma tissue residing in the bone marrow 
(Davidson et al. 2005). HepG2 cells were similarly isolated from liver tumor tissue 
(Aden et al. 1979). AC16 cells originated from ventricular cardiac tissue fused with 
fibroblasts infected with SV40 (Biedler et al. 1973). Despite their utility and ease of 
use, several limitations regarding use of cell lines should be taken into 
consideration. Firstly, as with a vast majority of immortalized cells, these lines are 
wrought with karyotypic abnormalities potentially confounding results (Spengler et 
al. 2002; Wong et al. 2000). Additionally, disease progresses in very different ways 
for ATTR amyloidosis patients, largely depending on their genetic background, 
including both driver mutation and potential disease modifiers. It is possible that 
these factors contribute to the response of target cells to destabilized TTRs or 
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other cell autonomous/non-autonomous factors in ways we do not yet understand. 
In line with this, our highlighted in Chapter 4, demonstrated that the expression of 
TTRL55P results in differential expression of a number of UPR-associated signaling 
factors which in turn, could further alter the cell. Despite this caveat, as the effect 
of these genetic variants remains unknown, it is presently impossible to assess 
their impact on target cell response. 
 A possible explanation for low variability across cell types dosed with TTRs 
could be reflected in the concentration used for dosing. In humans, serum levels 
of TTR are between 0.2-0.4 mg/mL. In the transcriptomic profiling experiment 
described herein, cells were dosed with 0.0125 mg/mL for 48 hours. Work by 
others have observed cell death with concentrations far greater than circulating 
levels (Reixach et al. 2004; Ueda et al. 2019). Originally, for these experiments a 
low concentration was used in order to detect the earliest instances of TTR-
mediated cell damage (i.e. a concentration at which cell toxicity/death would not 
be detectible). It is possible that a greater effect at the transcriptomic level could 
be observed by increasing the concentration of protein or the time for which cells 
were exposed. It remains to be seen however, how expression of putative TTR-
responsive genes will change by altering either parameter. Follow-up work will 
seek to multiplex/overlay ATACseq and transcriptomic data to identify common 
sites of differences upon TTR exposure.  
Data herein suggest that cells respond to overt stressors such as NaAsO2 
in a cell type-specific manner. This could result from the transcriptomic and 
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proteomic environment of the particular cell. In the instance of ER stress for 
example, the “chaperome” (all of the chaperones within a cell at a given moment) 
likely varies across tissue and cell types. Differences in the type and abundance 
of stress pathway components (e.g. protein folding quality control mechanisms) 
could force a cell to utilize a particular pathway to cope with a stressor (Sala et al. 
2017). This might explain the differences observed between SH-SY5Y and AC16 
cells upon NaAsO2 exposure. SH-SY5Y cell stress response appears to be largely 
driven by ER stress and protein folding quality control mechanisms while AC16 
cells exhibit differences in translational machinery (e.g. ribosome proteins).  
The observation that cells respond to NaAsO2 in a cell type-specific manner 
could likely be reflected in cells exposed to destabilized TTRs. In the instance of 
an extracellular stressor such as TTR aggregate deposition, differences in cell type 
response could result from differences in cell surface receptors (outlined in Figure 
5.4). Although the mechanism of TTR-mediated cell death remains unclear, one 
potential mechanism is that cell type-specific receptors interact with TTR 
aggregates and as a result trigger intracellular signaling cascades which eventually 
lead to cell death. Taking into consideration binding of protein aggregates with 
receptors, this postulation additionally evokes potential mechanisms for mutation-
specific organ tropism. Specifically regarding ATTR amyloidosis pathogenesis, 
cardiac-specific receptors could interact with cardiomyopathy-associated TTR 
aggregates with greater affinity than neuropathy-associated variants. If cell death 
were to occur via an overall physical compression-based mechanism, differences  
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Figure 5.4 Proposed mechanisms for putative TTR variant- and cell type-
specific transcriptional signatures of cellular stress.  
Diagram depicting potential mechanisms underlying cell type-specific responses 
to destabilized TTRs. Hepatic-derived TTRs could have varied structures, 
conformations, or modifications depending on their underlying mutation and 
proteostasis environment. These changes could result in differential binding 
affinities for cell type-specific ECMs and/or receptors.
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in extracellular matrix (ECM) components associated with each target cell type 
could interact with TTR aggregates with varying affinities (e.g. TTRL55P strongly 
interacting with Schwann cell ECMs) (Frantz et al. 2010).  
Differences in the binding affinities of TTR aggregates for cell type-specific 
receptors or ECM components may provide a mechanism for tissue tropism seen 
in patients with ATTR amyloidosis. It remains unclear however, how pathologically-
diverse TTRs might achieve differential affinities for a particular tissue or cell 
type/environment. Several post-translational modifications (PTMs) within TTR 
have been identified – most commonly, oxidation of the cysteine residue at position 
10 (Escher et al. 2007, Henze et al. 2015). Although the PTMs of TTR have been 
characterized from serum of patients, recent work from our group suggests that 
hepatic expression of mutant TTR correlates with differential expression of proteins 
involved in PTMs (Kingsbury et al. 2007). It is therefore possible that 
pathologically-diverse TTR variants could become differentially modified prior to 
secretion from the liver and in turn interact with tissue environments with greater 
or less affinity. Alternatively, in addition to PTM-associated proteins, our data 
demonstrates that hepatic expression of destabilized TTR can result in differential 
expression of many other proteins (Chapter 4). It is possible that these proteins 
could interact with their associated TTR variant and further mediate their 
interaction with specific environments. To address these proposed mechanisms, 
future studies should utilize biophysics and proteomics-based methodologies to 
probe differences in diverse TTR variants, including: available conformations, 
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PTMs, overall structure (including potential proteolytic cleavage events), and 
interacting protein partners.  
The work herein defines transcriptional signatures constituting exposure to 
destabilized, pathologically diverse TTRs. Through these efforts, we identified cell 
type-specific responses to the presence of TTR – a phenomenon similar to a 
variety of other stressors (e.g. NaAsO2 exposure). Moreover, we begin to profile 
distinct transcriptional differences resulting from exposure to each TTR. Future 
work will aim to utilize these variant specific TTR-mediated signatures in order to 
interrogate mechanisms underlying mutation-specific organ tropism – a 
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CHAPTER SIX. GENERAL DISCUSSION. 
We sought to utilize novel tools to understand the pathogenesis of ATTR 
amyloidosis at sites of TTR production and deposition. In doing so, this body of 
work develops and expands upon our laboratory’s iPSC-based model for studying 
ATTR amyloidosis, uncovers a novel hepatic gene signature in ATTR amyloidosis 
HLCs, explores the potential for UPR-modulating therapeutics in the treatment of 
systemic amyloid disease, and profiles the transcriptional response of multiple cell 
types to pathologically-diverse mutant TTRs. 
 Utilizing tools developed in Chapter 3, Chapter 4 addresses Aim 1, by 
demonstrating that hepatic production of destabilized TTR leads to alterations in 
the expression of proteostasis machinery. Follow-up work will involve 
understanding whether ER-resident stress sensors detect misfolded TTRs in this 
system to in turn upregulate UPR-associated signaling pathways. By surveying the 
transcriptional responses of target cell types to multiple TTRs in Chapter 5, we 
accomplish Aim 2, highlighting diverse cell type- and variant-specific responses to 
TTR exposure. Future experiments with regard to this work will seek to assess the 
specific mechanisms by which interaction with external TTR elicits target cell 
damage and/or stress responses (potential mechanisms outlined in Figure 5.4).  
 
6.1 FUTURE DIRECTIONS 
6.1.1 IPSCS AS A TOOL FOR NOVEL THERAPEUTIC DEVELOPMENT IN 
ATTR AMYLOIDOSIS 
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In Chapter 3, we describe the creation and characterization of a library of iPSCs 
derived from diverse patients with hereditary ATTR amyloidosis. Complementing 
our laboratory’s previously described iPSC-based model for the disorder, this 
catalog will serve as a valuable tool for studying novel aspects of disease 
pathogenesis.   
Through the directed differentiation of multiple patient-specific iPSC lines, 
we observed that destabilized, mutant TTR is present in conditioned hepatic media 
less than wild-type TTR (Figure 3.6) (Giadone et al. 2018). Barring differences in 
the sensitivity for antibodies used to pull down TTR prior to MS, this observation 
could reflect hepatic activation of UPR machinery. As discussed in Chapter 4, we 
uncovered that expression of TTRL55P results in differential expression of several 
genes linked to processes such as ER associated degradation. It is therefore 
possible that expression of misfolding-prone TTR variants can elicit the UPR and 
as a result, preferential degradation of the misfolded TTR protein relative to the 
wild-type. Given the diversity in disease phenotype across patients with different 
mutations, follow-up studies will investigate the proteostasis mechanisms evoked 
by different TTR mutations within hepatic cells. Expression of hyper-destabilized 
TTRs, which intracellularly misfold at greater rates (e.g. TTRA25T), may result in 
varying degrees or types of proteostasis factors upregulated (Hurshman Babbes 
et al. 2008). 
An alternative explanation for greater levels of wild-type compared to 
mutant TTR present in conditioned supernatant could reflect a novel allele-specific 
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bias in gene expression. It is possible that the wild-type TTR allele in patient 
hepatic cells is transcribed at greater levels than the mutant allele as a protective 
mechanism to in turn limit its concentration in circulation. Future scRNAseq 
experiments conducted on iPSC-derived HLCs may address this possibility.  
 
6.1.2 DEVELOPING NOVEL BIOMARKERS FOR ATTR AMYLOIDOSIS  
Despite a number of advances in the development of therapeutics for ATTR 
amyloidosis, effectiveness of treatments for the disease is limited by current 
diagnostics. As the primary cytotoxic species in the disease is low molecular 
weight oligomers (prefibrillar aggregates), damage is likely occurring in target 
organs long before a diagnosis is made (Reixach et al. 2004). Since the 
effectiveness of current treatments (including liver transplantation, kinetic 
stabilizers, and RNAi technologies) is limited by disease progression, novel 
biomarkers for ATTR amyloidosis are needed.  
 Recent work has proposed the use of serum levels of TTR as a potential 
marker for disease progression in patients with cardiomyopathy-associated ATTR 
amyloidosis (Hanson et al. 2018). Healthy individuals have circulating levels of 
TTR of approximately 0.2-0.4 mg/mL, while decreased concentrations were 
associated with worse disease outcome. The mechanism of this inverse correlation 
of serum TTR levels and disease progression however remain unclear. An 
alternative approach being developed utilizes TTR tetramer-specific fluorescently 
labeled small molecules to assess the percentage of natively folded tetrameric 
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TTR relative to total serum levels (Chen et al. 2016). With this method, the ratio of 
circulating tetramer to total TTR could assist in detecting early stages of TTR 
misfolding and disease progression (Chen et al. 2016). Additionally, as discussed 
in Chapter 4, hepatic expression of TTRL55P results in upregulation of TF. If this 
observation holds true in vivo, transferrin (or orthogonal metabolites) could aid in 
identifying potential ATTR amyloidosis patients.  
 
6.1.3 EMPLOYING THE ADAPTIVE UPR AS THERAPY 
Highlighted by our work in Chapter 4, hepatic expression of destabilized TTR 
correlates with transcriptional activation of the adaptive UPR. Moreover, achieving 
stress-independent activation of the UPR-associated ATF6 signaling pathway is 
capable of selectively decreasing the secretion of toxic TTRs (Chen et al. 2014; 
Plate et al. 2016; Shoulders et al. 2013). Recent work has demonstrated the ability 
of small molecule activators of ATF6 signaling to similarly decrease circulating 
levels of proteotoxic species (Chen et al. 2014; Glembotski et al. 2019; Shoulders 
et al. 2013). Future work will employ our library of diverse patient-specific iPSCs 
to determine the efficacy of this approach in decreasing hepatic secretion of mutant 
TTR across a number of genetic backgrounds.  
 Activation of the UPR is extraordinarily complex – with overlapping pathway 
components and downstream gene targets. At the same time, in the case of 
chronic stress, UPR activation can be linked to employment of pro-apoptotic 
machinery via PERK signaling (David and Ron 2011; Romine and Wiseman 2018). 
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Going forward, it will be critical to evaluate the potential for activators of the 
adaptive UPR to trigger cell death pathways. Important to note, the UPR is also 
context dependent – with outcomes specific to client proteins as well as cell type 
(Sala et al. 2017). Οur iPSC-based platform will allow for interrogation of small 
molecule-associated toxicity in a number of physiologically-relevant cell types.   
 Systemic amyloid diseases represent a large class of multi-system protein 
folding disorders involving the misfolding of many structurally distinct proteins 
(Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 1997; 
Merlini and Westermark 2004; Wechalekar et al. 2016). As such, the development 
of small molecule and chemical-genetic-based approaches for modulating 
proteostasis machinery could represent a broadly efficacious therapeutic strategy 
for this class of disorders with large unmet medical need. 
 
6.1.4 UNDERSTANDING STRESS RESPONSES IN DIVERSE CELL TYPES 
Much of Chapter 5 involves understanding the response of diverse target organ 
cell types to mutant, misfolding-prone TTRs. While the incidence of wild-type forms 
of the disease are expected to rise in the following years, ATTR amyloidosis (both 
wild-type and hereditary) is still considered a rare disease (Ando et al. 2005; 
Benson 2019; Gertz et al. 2015; Reixach et al. 2004; Ruberg and Berk 2012). 
Systemic amyloid diseases however, currently affect over 1 million individuals 
worldwide (Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 
1997; Merlini and Westermark 2004; Wechalekar et al. 2016). The overall 
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pathogenesis, involving the production of misfolded proteins by effector organs 
and deposition at distal target organs, is conserved across these diverse disorders 
(Blancas-Mejia and Ramirez-Alvarado 2013; Buxbaum 2004; Falk et al. 1997; 
Merlini and Westermark 2004; Wechalekar et al. 2016). Investigating the secretion 
and deposition of TTR aggregates in ATTR amyloidosis using iPSC-derived cell 
types, has the potential to lend insight into other multi-system protein folding 
disorders. 
  To this end, gene signatures developed in Chapter 5, involving the 
interaction of misfolded TTR with multiple cell types, can potentially aid in the 
development of robust in vitro models of systemic amyloid diseases. Future work 
should aim to understand similarities in transcriptional signatures resulting from 
exposure to diverse proteotoxic aggregates – from ATTR to LCs in AL amyloidosis. 
Once accomplished, these profiles can be employed as outputs for tracking 
damage and toxicity in future cell-based models for other protein folding disorders. 
 
6.2 Final conclusions 
In ATTR amyloidosis, misfolded TTR is produced from the liver where it 
subsequently travels throughout circulation and eventually deposits at downstream 
target organs. The work in this thesis employs novel tools to understand cell and 
molecular mechanisms contributing to the global pathogenesis of the disease – at 
sites of TTR production and deposition. Collectively, these data contribute to our 
hypothesis that intracellular expression of and extracellular exposure to 
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destabilized TTRs results in distinct cellular and molecular changes. The work 
herein will perhaps translate to novel therapeutics for and understandings of ATTR 
amyloidosis, other systemic amyloid diseases, and general/overall declines in 
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